Chronic Spinal Injury Repair by Olfactory Bulb Ensheathing Glia and Feasibility for Autologous Therapy Cintia Mun˜oz - Quiles , PhD , Fernando F. Santos-Benito , PhD , M. Beatriz Llamusı ' , PhD , and Almudena Ramo ' n-Cueto , MD , PhD Abstract Olfactory bulb ensheathing glia -LRB- OB-OEG -RRB-	1
Chronic Spinal Injury Repair by Olfactory Bulb Ensheathing Glia and Feasibility for Autologous Therapy Cintia Mun˜oz - Quiles , PhD , Fernando F. Santos-Benito , PhD , M. Beatriz Llamusı ' , PhD , and Almudena Ramo ' n-Cueto , MD , PhD Abstract Olfactory bulb ensheathing glia	1
Spinal Injury Repair by Olfactory Bulb Ensheathing Glia and Feasibility for Autologous Therapy Cintia Mun˜oz - Quiles , PhD , Fernando F. Santos-Benito , PhD , M. Beatriz Llamusı ' , PhD , and Almudena Ramo ' n-Cueto , MD , PhD Abstract	9
Spinal Injury Repair	9
Olfactory Bulb Ensheathing Glia and Feasibility for Autologous Therapy Cintia Mun˜oz - Quiles , PhD , Fernando F. Santos-Benito , PhD , M. Beatriz Llamusı ' , PhD , and Almudena Ramo ' n-Cueto , MD , PhD Abstract	33
Olfactory Bulb Ensheathing Glia	33
Feasibility for Autologous Therapy Cintia Mun˜oz	69
Feasibility	69
Autologous Therapy Cintia Mun˜oz	85
Quiles , PhD , Fernando F. Santos-Benito	119
PhD	159
M. Beatriz Llamusı '	164
PhD	185
Almudena Ramo ' n-Cueto , MD , PhD Abstract	194
Almudena Ramo ' n-Cueto , MD	194
Almudena Ramo '	194
PhD Abstract	221
OB-OEG	268
repair of spinal cord injury -LRB- SCI -RRB- in rats	284
repair	284
spinal cord injury -LRB- SCI -RRB- in rats	294
spinal cord injury -LRB- SCI -RRB-	294
spinal cord injury	294
SCI	314
rats	322
transplantation at acute or subacute -LRB- up to 45 days -RRB- stages	333
transplantation	333
acute or subacute -LRB- up to 45 days -RRB- stages	352
45 days	377
The most relevant clinical scenario in humans	394
The most relevant clinical scenario	394
humans	433
chronic SCI , in which no more major cellular or molecular changes occur at the injury site ; this occurs after the third month in rodents	453
chronic SCI	453
no more major cellular or molecular changes	475
the injury site	528
this	545
the third month in rodents	563
the third month	563
rodents	582
adult OB-OEG grafts	599
repair of severe chronic SCI	627
repair	627
severe chronic SCI	637
Rats with complete SCI that were transplanted with OB-OEG 4 months after injury	691
Rats	691
complete SCI	701
OB-OEG	742
4 months	749
injury	764
progressive improvement	781
motor function and axonal regeneration	808
motor function	808
axonal regeneration	827
different brainstem nuclei	852
the SCI site	897
A positive correlation between motor outcome and axonal regeneration	911
A positive correlation	911
motor outcome and axonal regeneration	942
motor outcome	942
axonal regeneration	960
a role	990
brainstem neurons	1001
the recovery	1022
Functional and histological outcomes	1036
transplantation	1094
subacute or chronic stages	1113
autologous transplantation	1147
a feasible approach	1177
there	1200
a time frame for patient stabilization and OEG preparation	1209
a time frame	1209
patient stabilization and OEG preparation	1226
patient stabilization	1226
OEG preparation	1252
the healing effects of OB-OEG on established injuries	1279
the healing effects	1279
OB-OEG on established injuries	1302
OB-OEG	1302
established injuries	1312
new therapeutic opportunities	1343
chronic SCI patients	1377
INTRODUCTION Most spinal cord injuries -LRB- SCIs -RRB-	1400
INTRODUCTION Most spinal cord injuries	1400
INTRODUCTION	1400
Most	1413
spinal cord injuries	1418
SCIs	1440
permanent and irreversible functional deficits	1452
The devastating prognosis for people experiencing severe SCI	1500
The devastating prognosis	1500
people experiencing severe SCI	1530
people	1530
severe SCI	1550
an impetus to search for therapies aimed at curing this chronic pathology	1574
therapies aimed at curing this chronic pathology	1599
therapies	1599
this chronic pathology	1625
the use of olfactory ensheathing glia -LRB- OEG -RRB- transplantation	1649
the use	1649
olfactory ensheathing glia -LRB- OEG -RRB- transplantation	1660
OEG	1688
a promising repair strategy	1712
There	1741
more than 40 articles that show positive effects of OEG after SCI of various types and severities -LRB- 1 -RRB-	1751
more than 40 articles	1751
positive effects of OEG	1783
positive effects	1783
OEG	1803
SCI of various types and severities -LRB- 1 -RRB-	1813
SCI	1813
various types and severities -LRB- 1 -RRB-	1820
various types and severities	1820
1	1850
most of these	1854
most	1854
these	1862
spinal cord trauma -LRB- 2Y9 -RRB- , including contusion -LRB- 10 -RRB-	1875
spinal cord trauma -LRB- 2Y9 -RRB-	1875
spinal cord trauma	1875
2Y9	1895
contusion -LRB- 10 -RRB-	1911
contusion	1911
10	1922
there	1931
13 studies that show no or limited beneficial effects	1941
13 studies	1941
no or limited beneficial effects	1962
no	1962
limited beneficial effects	1968
The differences	1996
the sources of cells , ages of the animals , and the methods used for culture and transplantation	2028
the sources of cells	2028
the sources	2028
cells	2043
ages of the animals	2050
ages	2050
the animals	2058
the methods used for culture and transplantation	2075
the methods	2075
culture and transplantation	2096
the third week in vitro , adult rodent olfactory bulb -LRB- OB -RRB-	2131
the third week in vitro , adult rodent olfactory bulb	2131
third week	2135
OB	2185
OEG become senescent and have an associated change in phenotype -LRB- 11 -RRB-	2189
OEG	2189
an associated change in phenotype -LRB- 11 -RRB-	2219
an associated change	2219
phenotype -LRB- 11 -RRB-	2243
phenotype	2243
11	2254
grafting of older cultures	2265
grafting	2265
older cultures	2277
cell survival and/or migration -LRB- 12Y15 -RRB-	2307
cell survival and/or migration	2307
cell survival	2307
migration	2328
12Y15	2339
OEG	2362
the olfactory bulb -LRB- central -RRB-	2371
the olfactory bulb	2371
central	2391
the epithelium -LRB- peripheral -RRB-	2408
the epithelium	2408
peripheral	2425
a debated issue	2445
OEG	2480
they	2509
inferior migratory and growth-promoting properties -LRB- 16Y18 -RRB- compared with bulbar OEG -LRB- 2Y9 -RRB-	2527
inferior migratory and growth-promoting properties	2527
16Y18	2579
bulbar OEG -LRB- 2Y9 -RRB-	2600
bulbar OEG	2600
2Y9	2612
these studies and the prospect for autologous therapy	2627
these studies	2627
the prospect for autologous therapy	2645
the prospect	2645
autologous therapy	2662
we	2682
adult nonsenescent OEG of bulbar origin	2690
adult nonsenescent OEG	2690
bulbar origin	2716
this study	2733
most of the previous studies	2748
most	2748
the previous studies	2756
OEG	2778
SCI -LRB- the acute stage -RRB-	2823
SCI	2823
the acute stage	2828
many patients	2854
several weeks or even months for clinical stabilization	2873
several weeks	2873
months for clinical stabilization	2895
months	2895
clinical stabilization	2906
a delayed transplant paradigm	2939
autologous transplantation	3017
cell preparation	3059
time	3085
an intervention several months after SCI	3098
an intervention several months	3098
SCI	3135
a more realistic paradigm	3142
Experimental OB-OEG grafting	3169
7 and 30 days -LRB- 10 , 19 -RRB-	3219
7 and 30 days	3219
10	3234
19	3238
45 days -LRB- 20 -RRB- , which has been considered to be the subacute stage -LRB- 21 , 22 -RRB-	3259
45 days -LRB- 20 -RRB-	3259
20	3268
the subacute stage -LRB- 21 , 22 -RRB-	3305
the subacute stage	3305
21	3325
22	3329
the absence of further manipulation and when no more cellular and molecular changes occur	3337
the absence of further manipulation	3337
the absence	3337
further manipulation	3352
no more cellular and molecular changes	3382
more cellular	3385
molecular changes	3403
SCIs	3428
the chronic stage , which is after the third month in rodents -LRB- 21 , 22 -RRB-	3457
the chronic stage	3457
the third month in rodents -LRB- 21 , 22 -RRB-	3491
the third month	3491
rodents -LRB- 21 , 22 -RRB-	3510
rodents	3510
21	3519
22	3523
we	3534
the repair efficacy of OB-OEG grafted at the chronic stage into the injury site , and after complete SCI to evaluate axonal regeneration rather than plasticity of spared fibers	3548
the repair efficacy of OB-OEG grafted at the chronic stage into the injury site , and after complete SCI to evaluate axonal regeneration	3548
the repair efficacy	3548
OB-OEG grafted at the chronic stage into the injury site , and after complete SCI to evaluate axonal regeneration	3571
OB-OEG	3571
the chronic stage into the injury site , and after complete SCI	3589
the chronic stage	3589
the injury site	3612
complete SCI	3639
axonal regeneration	3664
plasticity of spared fibers	3696
plasticity	3696
spared fibers	3710
We	3725
functional and histological outcomes	3742
the subacute stage	3796
the regeneration of relevant descending motor tracts at both subacute and chronic stages	3830
the regeneration	3830
relevant descending motor tracts at both subacute and chronic stages	3850
relevant descending motor tracts	3850
both subacute and chronic stages	3886
both subacute	3886
chronic stages	3904
MATERIALS AND METHODS	3921
The experimental procedures	3943
the recommendations of the European Union and the United States Department of Health	3982
the recommendations of the European Union	3982
the recommendations	3982
the European Union	4005
the United States Department of Health	4028
the United States Department	4028
Health	4060
the care and use of laboratory animals	4071
the care and use	4071
laboratory animals	4091
the Ethics Committee of our institution	4131
the Ethics Committee	4131
our institution	4155
OEG Cultures	4172
Adult OBs	4190
Primary cultures of OB-OEG	4200
Primary cultures	4200
OB-OEG	4220
the first 2 olfactory bulb layers of 2	4246
the first 2 olfactory bulb layers	4246
2	4283
2.5-month-old Wistar Hannover rats -LRB- Harlan Laboratories , Barcelona , Spain -RRB-	4289
2.5-month-old Wistar Hannover rats	4289
Harlan Laboratories	4325
Barcelona	4346
Spain	4357
p75 receptorYexpressing OB-OEG	4365
7 days	4410
2 , 11	4456
2	4456
11	4459
They	4464
D/F -10 S -LRB- 1:1 DMEM : Ham F-12 ; Gibco-Invitrogen , Madrid , Spain ; 10 % fetal bovine serum -RRB-	4486
D/F -10 S	4486
1:1 DMEM : Ham F-12 ; Gibco-Invitrogen , Madrid , Spain ; 10 % fetal bovine serum	4495
1:1 DMEM	4495
Ham F-12 ; Gibco-Invitrogen , Madrid , Spain ; 10 % fetal bovine serum	4504
Ham F-12	4504
Gibco-Invitrogen , Madrid , Spain ; 10 % fetal bovine serum	4514
Gibco-Invitrogen , Madrid , Spain	4514
10 % fetal bovine serum	4547
37-C , 5 % carbon dioxide	4574
37-C	4574
5 % carbon dioxide	4580
2 days after purification	4602
2 days	4602
purification	4615
2 µmol/L forskolin -LRB- Sigma - Aldrich Quı ' mica , Madrid , Spain -RRB- and 20 µg/mL bovine pituitary extract -LRB- Biomedical Technologies , Inc , Stoughton , MA -RRB-	4629
2 µmol/L forskolin -LRB- Sigma - Aldrich Quı ' mica , Madrid , Spain -RRB-	4629
2 µmol/L forskolin	4629
Sigma	4649
Aldrich Quı ' mica , Madrid , Spain	4656
Aldrich Quı ' mica	4656
Aldrich Quı '	4656
Madrid , Spain	4674
20 µg/mL bovine pituitary extract -LRB- Biomedical Technologies , Inc , Stoughton , MA -RRB-	4693
20 µg/mL bovine pituitary extract	4693
20 µg/mL	4693
Biomedical Technologies	4728
Inc	4753
Stoughton , MA	4758
Pure p75-OEG	4785
less than 2 weeks	4816
senescence -LRB- 11 -RRB-	4843
senescence	4843
11	4855
Cells	4860
the flasks	4885
bisbenzimide -LRB- Hoechst 33342 ; Sigma-Aldrich Quı ' mica -RRB-	4910
bisbenzimide	4910
Hoechst 33342 ; Sigma-Aldrich Quı ' mica	4924
Hoechst 33342	4924
Sigma-Aldrich Quı ' mica	4939
Sigma-Aldrich	4939
Quı ' mica	4953
Quı '	4953
a density of 100,000 cells/µL	4984
a density	4984
100,000 cells/µL	4997
Dulbecco modified Eagle medium -LRB- DMEM -RRB- , as previously described -LRB- 2 , 4 , 23 , 24 -RRB-	5017
Dulbecco	5017
Eagle medium -LRB- DMEM -RRB- , as previously described -LRB- 2 , 4 , 23 , 24 -RRB-	5035
Eagle medium -LRB- DMEM -RRB- , as previously described	5035
Eagle medium	5035
DMEM	5049
2 , 4 , 23 , 24	5081
2	5081
4	5084
23	5087
24	5091
Surgery and OB-OEG Transplantation Adult female Wistar Hannover rats -LRB- aged 2.5 Y3 months , weighing 200-230 g , n = 28 -RRB- were anesthetized with isoflurane and N2 : O2 -LRB- 40:60 -RRB- , and a laminectomy to expose the T8 to T9 segments	5096
Surgery and OB-OEG Transplantation Adult	5096
female Wistar Hannover rats -LRB- aged 2.5 Y3 months , weighing 200-230 g , n = 28 -RRB-	5137
female Wistar Hannover rats -LRB- aged 2.5 Y3 months ,	5137
female Wistar Hannover rats	5137
aged 2.5 Y3 months	5166
aged 2.5	5166
Y3 months	5174
200-230 g , n = 28 -RRB-	5194
200-230 g	5194
n = 28	5205
n	5205
28	5209
anesthetized with isoflurane and N2 : O2 -LRB- 40:60 -RRB- , and a laminectomy to expose the T8 to T9 segments	5218
anesthetized with isoflurane and N2	5218
anesthetized	5218
isoflurane and N2	5236
O2 -LRB- 40:60 -RRB- , and a laminectomy to expose the T8 to T9 segments	5254
O2	5254
40:60	5258
a laminectomy to expose the T8 to T9 segments	5270
the T8	5294
T9 segments	5304
22 of the animals	5334
22	5334
the animals	5340
the dura	5353
the spinal cords	5377
microscissors	5426
The stumps	5441
completeness of the lesion -LRB- Fig. 1A -RRB- -LRB- 4 -RRB-	5474
completeness	5474
the lesion -LRB- Fig. 1A -RRB- -LRB- 4 -RRB-	5490
the lesion -LRB- Fig. 1A -RRB-	5490
the lesion	5490
Fig. 1A	5502
4	5512
The paraplegic animals	5516
3 groups : 1 -RRB- subacute -LRB- SA -RRB- , 2 -RRB- chronic -LRB- Chr -RRB- , and 3 -RRB- nontransplanted -LRB- Non-T -RRB- in a second surgery	5562
3 groups	5562
1 -RRB- subacute -LRB- SA -RRB- , 2 -RRB- chronic -LRB- Chr -RRB- , and 3 -RRB- nontransplanted -LRB- Non-T -RRB- in a second surgery	5572
subacute	5575
-LRB- SA -RRB- ,	5584
-LRB- SA -RRB-	5584
2 -RRB- chronic -LRB- Chr -RRB- , and 3 -RRB- nontransplanted -LRB- Non-T -RRB- in a second surgery	5590
2 -RRB- chronic -LRB- Chr -RRB- , and 3 -RRB- nontransplanted -LRB- Non-T -RRB- in a second	5590
chronic	5593
-LRB- Chr -RRB- , and	5601
-LRB- Chr -RRB-	5601
3 -RRB- nontransplanted -LRB- Non-T -RRB- in a second	5612
3 -RRB- nontransplanted -LRB- Non-T -RRB- in	5612
Non-T	5632
a second	5642
surgery	5651
The SA rats -LRB- n = 5 -RRB-	5660
The SA rats	5660
n	5673
5	5677
p75 OB-OEG at 1 month , and Chr rats -LRB- n = 5 -RRB-	5703
p75 OB-OEG	5703
1 month , and Chr rats -LRB- n = 5 -RRB-	5717
1 month	5717
Chr rats	5730
n	5740
5	5744
4 months	5750
SCI	5765
Non-T animals -LRB- n = 12 -RRB-	5770
Non-T animals	5770
n	5785
12	5789
DMEM	5838
1 -LRB- n = 6 -RRB- or 4 -LRB- n = 6 -RRB-	5849
1	5849
n	5852
6	5856
4	5862
n	5865
6	5869
months	5872
the sham-operated group	5883
6 more animals	5908
a second surgery	5956
1 -LRB- n = 3 -RRB- and 4 -LRB- n = 3 -RRB- months	5979
1 -LRB- n = 3 -RRB-	5979
1	5979
n	5982
3	5986
4 -LRB- n = 3 -RRB- months	5993
4	5993
n	5996
3	6000
months	6003
the second surgery	6014
the connective tissue that formed underneath the resin bridge and above the spinal cord -LRB- Fig. 1D -RRB-	6034
the connective tissue	6034
the resin bridge	6079
the spinal cord -LRB- Fig. 1D -RRB-	6106
the spinal cord	6106
Fig. 1D	6123
the injury region	6154
Glial and fibrous scars , created between the spinal cord stumps ,	6173
Glial and fibrous scars	6173
the spinal cord stumps	6214
Fig. 1E	6256
The OB-OEG	6266
both caudal and rostral intact spinal cord stumps	6311
1 mm from the stump border -LRB- Fig. 1F -RRB- , as previously described -LRB- 4 , 23 -RRB-	6365
1 mm	6365
the stump border -LRB- Fig. 1F -RRB- , as previously described	6375
the stump border -LRB- Fig. 1F -RRB-	6375
the stump border	6375
Fig. 1F	6393
4	6428
23	6431
Cells	6436
the midline of each stump	6459
the midline	6459
each stump	6474
ventral to dorsal , into 4 sites at 1.3 , 1.0 , 0.8 , and 0.5 mm	6491
dorsal	6502
4 sites at 1.3 , 1.0 , 0.8 , and 0.5	6515
4 sites	6515
1.3 , 1.0 , 0.8 , and 0.5	6526
1.3	6526
1.0 , 0.8 , and 0.5	6531
Each site	6567
0.5 µL of 50,000 OEG -LRB- 200,000 per stump -RRB-	6586
0.5 µL	6586
50,000 OEG -LRB- 200,000 per stump -RRB-	6596
50,000 OEG	6596
200,000 per stump	6608
200,000	6608
stump	6620
Nontransplanted animals	6628
0.5 µL of DMEM	6671
0.5 µL	6671
DMEM	6681
sham controls	6699
both surgeries	6735
spinal cords	6751
durafilm -LRB- Ferrosan , London , UK -RRB-	6782
durafilm	6782
Ferrosan	6792
London	6802
UK	6810
Vertebral columns	6815
a resin bridge between adjacent vertebrae -LRB- Fig. 1C -RRB- made of an autopolymerizing acrylic resin -LRB- Duralay ; Reliance Dental Manufacturing Co , Worth , IL -RRB- -LRB- 25 , 26 -RRB-	6857
a resin bridge	6857
adjacent vertebrae -LRB- Fig. 1C -RRB- made of an autopolymerizing acrylic resin -LRB- Duralay ; Reliance Dental Manufacturing Co , Worth , IL -RRB- -LRB- 25 , 26 -RRB-	6880
adjacent vertebrae	6880
Fig. 1C	6900
an autopolymerizing acrylic resin -LRB- Duralay ; Reliance Dental Manufacturing Co , Worth , IL -RRB- -LRB- 25 , 26 -RRB-	6917
an autopolymerizing acrylic resin -LRB- Duralay ; Reliance Dental Manufacturing Co , Worth , IL -RRB-	6917
an autopolymerizing acrylic resin	6917
Duralay ; Reliance Dental Manufacturing Co	6952
Duralay	6952
Reliance Dental Manufacturing Co	6961
Worth , IL	6995
Worth	6995
IL	7002
25	7007
26	7011
Animal Care , Physiotherapy , and Rehabilitation	7016
Animal Care	7016
Physiotherapy	7029
Rehabilitation	7048
surgery	7081
1 mL of Ringer 's lactate solution and analgesic magnesium metamizol -LRB- Nolotil , Boehringer Ingelheim , Barcelona , Spain -RRB-	7090
1 mL	7090
Ringer 's lactate solution and analgesic magnesium metamizol -LRB- Nolotil , Boehringer Ingelheim , Barcelona , Spain -RRB-	7098
Ringer 's lactate solution and analgesic magnesium metamizol	7098
Ringer 's	7098
Nolotil	7159
Boehringer Ingelheim	7168
Barcelona , Spain	7190
An antibiotic , Augmentin -LRB- amoxicillin/clavulanic acid , 1 g/200 mg ; GlaxoSmithKline , Madrid , Spain -RRB-	7242
An antibiotic	7242
Augmentin -LRB- amoxicillin/clavulanic acid , 1 g/200 mg ; GlaxoSmithKline , Madrid , Spain -RRB-	7257
Augmentin	7257
amoxicillin/clavulanic acid , 1 g/200 mg ; GlaxoSmithKline , Madrid , Spain	7268
amoxicillin/clavulanic acid	7268
1 g/200 mg ; GlaxoSmithKline	7297
1 g/200 mg	7297
GlaxoSmithKline	7309
Madrid , Spain	7326
every 8 hours	7378
Urinary bladder	7393
4 times a day	7432
4 times	7432
a day	7440
autonomous voidance and then once daily	7452
autonomous voidance	7452
then once daily	7476
Detailed postoperative care	7493
27	7541
paraplegic rats	7554
good condition	7573
they	7589
active and passive range of motion	7603
active and passive range	7603
motion	7631
Active range of motion	7639
Active range	7639
motion	7655
the	7682
test -LRB- Appendix 1 -RRB-	7695
test	7695
Appendix 1	7701
once a week	7713
Daily passive range of motion	7726
Daily passive range	7726
motion	7749
movement of joints	7765
movement	7765
joints	7777
the level of injury -LRB- 25 times each joint -RRB- and massages of muscles and skin	7790
the level of injury -LRB- 25 times each joint -RRB-	7790
the level	7790
injury -LRB- 25 times each joint -RRB-	7803
injury	7803
25 times each joint	7811
25 times	7811
each joint	7820
massages of muscles and skin	7836
massages	7836
muscles and skin	7848
bone prominences	7870
All animals	7888
12 months	7928
the first surgery -LRB- lesion surgery -RRB-	7944
the first surgery	7944
lesion surgery	7963
a third surgery for tracer injection -LRB- see below -RRB-	7996
a third surgery	7996
tracer injection	8016
All paraplegic animals with a complete lesion	8046
All paraplegic animals	8046
a complete lesion	8074
good and stable clinical condition for 1 year	8116
good and stable clinical condition	8116
1 year	8155
paraplegia	8169
animals	8181
2 additional surgeries , one for OB-OEG transplantation and another for tracer injection	8193
2 additional surgeries	8193
one for OB-OEG transplantation	8217
one	8217
OB-OEG transplantation	8225
another for tracer injection	8252
another	8252
tracer injection	8264
the time of the last surgery	8285
the time	8285
the last surgery	8297
the animals	8315
15 months	8367
Animal care	8383
those used for humans -LRB- 27 -RRB-	8412
those	8412
humans -LRB- 27 -RRB-	8427
humans	8427
27	8435
Functional Analysis A detailed description of the climbing test used in this study	8440
Functional Analysis	8440
A detailed description of the climbing test	8460
A detailed description	8460
the climbing test	8486
this study	8512
and	8551
Appendix 1	8571
supplemental data -LRB- Video , Supplemental Digital Content 1 , http://links.lww.com/NEN/A62 -RRB-	8599
supplemental data	8599
Video	8618
Supplemental Digital Content 1 , http://links.lww.com/NEN/A62	8625
Supplemental Digital Content 1	8625
http://links.lww.com/NEN/A62	8657
Training	8688
the animals	8710
1 month	8727
the first surgery	8759
Comparison of the performance of transplanted and Non-T rats	8778
Comparison	8778
the performance of transplanted and Non-T rats	8792
the performance	8792
transplanted and Non-T rats	8811
transplanted	8811
Non-T rats	8828
1	8847
month	8849
the first surgery -LRB- lesion -RRB- -LRB- Fig. 2 -RRB-	8861
the first surgery -LRB- lesion -RRB-	8861
the first surgery	8861
lesion	8880
Fig. 2	8889
Tracer Injection	8898
12 months	8918
lesion	8934
all animals	8942
a third surgery	8964
tracer injection	8984
A cocktail of 25 % horseradish peroxidase and 5 % wheat germ agglutininYhorseradish peroxidase -LRB- Sigma-Aldrich Quı ' mica -RRB- in 0.9 % NaCl	9002
A cocktail of 25 % horseradish peroxidase and 5 % wheat germ agglutininYhorseradish peroxidase	9002
A cocktail	9002
25 % horseradish peroxidase and 5 % wheat germ agglutininYhorseradish peroxidase	9016
25 % horseradish peroxidase	9016
5 % wheat germ agglutininYhorseradish peroxidase	9047
5 % wheat	9047
germ agglutininYhorseradish peroxidase	9056
Sigma-Aldrich Quı ' mica	9096
Sigma-Aldrich Quı '	9096
0.9 % NaCl	9123
the caudal stump	9167
0.5 cm	9188
its edge as	9200
peroxidase	9233
13 sites -LRB- 0.1 µL/site -RRB-	9262
13 sites	9262
0.1 µL/site	9272
the midline -LRB- 5 injections -RRB-	9303
the midline	9303
5 injections	9316
0.8 mm	9337
the left and right -LRB- 4 injections in each side -RRB-	9347
the left and right	9347
4 injections in each side	9367
4 injections	9367
each side	9383
2 , 1.6 , 1.2 , 0.8 , and 0.4 mm in the midline ; 1.6 , 1.2 , 0.8 , 0.4 mm in left and right sides	9397
2	9397
1.6	9400
1.2	9405
0.8	9410
0.4 mm in the midline	9419
0.4 mm	9419
the midline	9429
1.6	9442
1.2	9447
0.8	9452
0.4 mm in left and right sides	9457
0.4 mm	9457
left and right sides	9467
Rats	9489
48 hours	9518
perfusion	9534
This retrograde tracer	9545
axons either passing through or terminating at the site of injection	9586
axons	9586
the site of injection	9633
the site	9633
injection	9645
it	9663
axons	9677
at least 0.5 cm	9696
the lesion	9719
Histological Processing Animals	9731
4 % paraformaldehyde	9782
the spinal cords and brainstems	9803
the spinal cords	9803
brainstems	9824
5 hours	9868
Coronal sections of the brainstems and longitudinal sagittal sections of the spinal cords	9877
Coronal sections of the brainstems	9877
Coronal sections	9877
the brainstems	9897
longitudinal sagittal sections of the spinal cords	9916
longitudinal sagittal sections	9916
the spinal cords	9950
a cryostat -LRB- -20 °C , 20-µm sections -RRB-	9979
a cryostat	9979
-20 °C , 20-µm sections	9991
-20 °C	9991
20-µm sections	9998
Consecutive sections of the whole structures	10015
Consecutive sections	10015
the whole structures	10039
different slides	10080
peroxidase detection and immunohistochemistry	10115
peroxidase detection	10166
the entire brainstem	10188
20 µm	10226
sections	10237
each region of interest	10284
each region	10284
interest	10299
peroxidase detection	10313
sections -LRB- 100 µm -RRB-	10350
sections	10350
100 µm	10360
the entire brainstem	10391
these sections	10416
the peroxidase-labeled somata	10432
the chromogen diaminobenzidine -LRB- Vector Laboratories , Burlingame , CA -RRB-	10481
the chromogen diaminobenzidine	10481
Vector Laboratories	10513
Burlingame	10534
CA	10546
the signal	10563
sections	10575
an antibody against wheat germ agglutinin -LRB- anti-wheat germ agglutinin , 1:250 , overnight at 4-C -RRB- and a biotinylated-conjugated secondary antibody -LRB- 1:200 , 45 minutes -RRB- , then stained using the Vectastain Elite ABC standard kit -LRB- antibodies and kit from Vector Laboratories -RRB-	10607
an antibody	10607
wheat germ agglutinin -LRB- anti-wheat germ agglutinin , 1:250 , overnight at 4-C -RRB- and a biotinylated-conjugated secondary antibody -LRB- 1:200 , 45 minutes -RRB-	10627
wheat germ agglutinin	10627
anti-wheat germ agglutinin , 1:250	10650
anti-wheat germ agglutinin	10650
1:250	10678
4-C	10698
a biotinylated-conjugated secondary antibody	10707
1:200 , 45 minutes	10753
1:200	10753
45 minutes	10760
the Vectastain Elite ABC standard kit -LRB- antibodies and kit from Vector Laboratories -RRB-	10792
the Vectastain Elite ABC standard kit	10792
antibodies and kit from Vector Laboratories	10831
antibodies and kit	10831
Vector Laboratories	10855
Spinal cord sections of 3 animals per group -LRB- n = 9 -RRB-	10877
Spinal cord sections of 3 animals per group	10877
Spinal cord sections	10877
3 animals per group	10901
3 animals	10901
group	10915
n	10922
9	10926
peroxidase	10994
the injury region -LRB- Figure , Supplemental Digital Content 2 , http://links.lww.com/NEN/A63 -RRB-	11021
the injury region	11021
Figure , Supplemental Digital Content 2 , http://links.lww.com/NEN/A63	11040
Figure	11040
Supplemental Digital Content 2	11048
http://links.lww.com/NEN/A63	11080
Spinal cord sections containing the entire injury region and 2 segments above and below -LRB- i.e. from T6 to T10 -RRB-	11111
Spinal cord sections containing the entire injury region and 2 segments above and below	11111
Spinal cord sections	11111
the entire injury region and 2 segments	11143
the entire injury region	11143
2 segments	11172
i.e. from T6 to T10	11200
i.e.	11200
T6	11210
T10	11216
Appendix 2	11241
the sections	11262
we	11304
the precise location of each section	11322
the precise location	11322
each section	11346
the type of analysis -LRB- see below -RRB-	11373
the type	11373
analysis	11385
these sections	11407
4 °C with the following primary antibodies	11450
4 °C	11450
the following primary antibodies	11459
polyclonal rabbit anti-glial fibrillary acidic protein -LRB- -LSB- GFAP -RSB- Dako , Barcelona , Spain ; 1:500 -RRB- to label reactive astroglia and to delimit the glial scar ; monoclonal mouse anti-neurofilament -LRB- -LSB- NFL -RSB- Hybridoma Bank RT 97 , Iowa City , IA ; 1:1500 -RRB- to stain axons ; and polyclonal rabbit antiYRat S100 -LRB- Dako ; 1:100 -RRB- to distinguish OEG	11493
polyclonal rabbit anti-glial fibrillary acidic protein -LRB- -LSB- GFAP -RSB- Dako , Barcelona , Spain ; 1:500 -RRB- to label reactive astroglia and to delimit the glial scar	11493
polyclonal rabbit	11493
anti-glial fibrillary acidic protein -LRB- -LSB- GFAP -RSB- Dako , Barcelona , Spain ; 1:500 -RRB-	11511
anti-glial fibrillary acidic protein	11511
-LSB- GFAP -RSB- Dako	11549
-LSB- GFAP	11549
Dako	11556
Barcelona , Spain ; 1:500	11562
Barcelona , Spain	11562
1:500	11580
reactive astroglia	11596
the glial scar	11630
monoclonal mouse anti-neurofilament -LRB- -LSB- NFL -RSB- Hybridoma Bank RT 97 , Iowa City , IA ; 1:1500 -RRB- to stain axons	11646
monoclonal mouse anti-neurofilament	11646
-LSB- NFL -RSB- Hybridoma Bank RT 97 , Iowa City	11683
-LSB- NFL -RSB- Hybridoma Bank RT 97	11683
Iowa City	11711
IA ; 1:1500	11722
IA	11722
1:1500	11726
axons	11743
polyclonal rabbit antiYRat S100 -LRB- Dako ; 1:100 -RRB- to distinguish OEG	11754
polyclonal rabbit antiYRat S100	11754
Dako ; 1:100	11787
Dako	11787
1:100	11793
OEG	11815
The following day	11820
sections	11839
the respective secondary antibodies conjugated with Texas Red -LRB- Jackson ImmunoResearch , West Grove , PA ; 1:500 -RRB- or Oregon Green -LRB- Molecular ProbesYInvitrogen , Barcelona , Spain ; 1:500 -RRB- for 45 minutes at room temperature	11868
the respective secondary antibodies	11868
Texas Red -LRB- Jackson ImmunoResearch , West Grove , PA ; 1:500 -RRB- or Oregon Green -LRB- Molecular ProbesYInvitrogen , Barcelona , Spain ; 1:500 -RRB-	11920
Texas Red	11920
Jackson ImmunoResearch , West Grove	11931
Jackson ImmunoResearch	11931
West Grove	11955
PA ; 1:500	11967
PA	11967
1:500	11971
Oregon Green	11981
Molecular ProbesYInvitrogen , Barcelona	11995
Molecular ProbesYInvitrogen	11995
Barcelona	12024
Spain ; 1:500	12035
Spain	12035
1:500	12042
45 minutes at room temperature	12053
45 minutes	12053
room temperature	12067
sections	12093
Fluoromount -LRB- SouthernBiotech , Birmingham , AL -RRB-	12120
Fluoromount	12120
SouthernBiotech	12133
Birmingham	12150
AL	12162
Quantification Methods at the Injury Site Quantification of Tissue Degeneration Every fifth section of the entire spinal cord separated by 100 µm -LRB- N = 28/animal -RRB-	12184
Quantification Methods	12184
the Injury Site Quantification of Tissue Degeneration Every fifth section of the entire spinal cord separated by 100 µm -LRB- N = 28/animal -RRB-	12210
the Injury Site Quantification	12210
Tissue Degeneration Every fifth section of the entire spinal cord separated by 100 µm -LRB- N = 28/animal -RRB-	12244
Tissue Degeneration	12244
Every fifth section of the entire spinal cord	12264
Every fifth section	12264
the entire spinal cord	12287
100 µm	12323
Fibrous scar and cavities , a direct consequence of tissue degeneration ,	12360
Fibrous scar and cavities	12360
a direct consequence of tissue degeneration	12387
a direct consequence	12387
tissue degeneration	12411
GFAP negative	12436
GFAP	12436
the volume of GFAP-negative tissue	12483
the volume	12483
GFAP-negative tissue	12497
the injury site	12521
each GFAPlabeled section	12541
the lesion area	12567
a Leica microscope	12605
each section	12628
fibrous scar and cystic areas -LRB- GFAP , negative tissue -RRB- were outlined and measured -LRB- square micrometers -RRB- using the image analysis program Metamorph , and volumes	12642
fibrous scar and cystic areas -LRB- GFAP , negative tissue -RRB- were outlined and measured -LRB- square micrometers -RRB-	12642
fibrous scar and cystic areas -LRB- GFAP , negative tissue -RRB- were outlined and measured	12642
fibrous scar and cystic areas	12642
GFAP , negative tissue	12673
GFAP	12673
negative tissue	12679
square micrometers	12724
the image analysis program Metamorph , and volumes	12750
the image analysis program Metamorph	12750
the image analysis program	12750
Metamorph	12777
volumes	12792
as previously described -LRB- 28 , 29 -RRB-	12816
as previously	12816
28 , 29	12841
28	12841
29	12845
individual subvolumes , which correspond to the area in 1 section multiplied by the distance to the next -LRB- 100 µm -RRB- ,	12859
individual subvolumes	12859
the area in 1 section multiplied by the distance to the next -LRB- 100 µm -RRB-	12902
the area	12902
1 section multiplied by the distance to the next -LRB- 100 µm -RRB-	12914
1 section	12914
the distance	12938
the next -LRB- 100 µm -RRB-	12954
the next	12954
100 µm	12964
Quantification of Axons Sections adjacent to those used for the quantification of tissue degeneration -LRB- n = 28 , also separated by 100 µm -RRB-	12986
Quantification	12986
Axons Sections adjacent to those used for the quantification of tissue degeneration	13004
Axons Sections	13004
those	13031
the quantification of tissue degeneration	13046
the quantification	13046
tissue degeneration	13068
n = 28 , also separated by 100 µm	13089
n	13089
28	13093
100 µm	13115
anti-GFAP	13148
the borders	13168
the GFAP-positive glial scar	13183
anti-NFL	13221
axons	13240
Quantification	13247
the GFAP-negative fibrous scar	13278
the total number of pixels in this region determined by image analysis	13315
the total number	13315
pixels in this region determined by image analysis	13335
pixels	13335
this region determined by image analysis	13345
this region	13345
image analysis	13371
the percentages of those showing anti-NFL labeling	13387
the percentages	13387
those showing anti-NFL labeling	13406
those	13406
anti-NFL labeling	13420
The averages of the percentages per rat	13455
The averages	13455
the percentages per rat	13471
the percentages	13471
rat	13491
group comparisons	13509
Quantification of Neuronal Regeneration Every fifth section of the whole brainstem	13528
Quantification	13528
Neuronal Regeneration Every fifth section of the whole brainstem	13546
Neuronal Regeneration	13546
Every fifth section of the whole brainstem	13568
Every fifth section	13568
the whole brainstem	13591
quantifying numbers of peroxidase-traced neurons	13624
quantifying numbers	13624
peroxidase-traced neurons	13647
sections	13682
order	13709
the precise location within the brainstem of each section	13716
the precise location	13716
the brainstem of each section	13744
the brainstem	13744
each section	13761
specific nuclei	13789
the Paxinos and Watson atlas -LRB- 30 -RRB-	13835
the Paxinos and Watson atlas	13835
30	13865
A distance between sections of 100 µm	13870
A distance	13870
sections of 100 µm	13889
sections	13889
100 µm	13901
double or triple counting of the same neuron	13916
double or triple counting	13916
the same neuron	13945
adjacent sections	13964
Peroxidase-containing somata	13983
their cytoplasmic brown diaminobenzidine chromogen reaction	14031
a Leica microscope	14109
Sections used for counting in each nucleus , and per rat	14129
Sections	14129
each nucleus	14159
rat	14181
1 -RRB- red nucleus : 14 -LRB- left -RRB- and 14 -LRB- right -RRB- ; 2 -RRB- reticular formation : 66 ; 3 -RRB- locus coeruleus : 20 -LRB- left -RRB- and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5 -RRB- raphe nucleus : 60	14195
1 -RRB- red nucleus : 14 -LRB- left -RRB- and 14 -LRB- right -RRB- ; 2 -RRB- reticular formation : 66 ; 3 -RRB- locus coeruleus : 20 -LRB- left -RRB- and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5 -RRB-	14195
red	14198
nucleus :	14202
nucleus	14202
14 -LRB- left -RRB- and 14 -LRB- right -RRB- ; 2 -RRB- reticular formation : 66 ; 3 -RRB- locus coeruleus : 20 -LRB- left -RRB- and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5 -RRB-	14211
14 -LRB- left -RRB-	14211
14 -LRB- right -RRB- ; 2 -RRB- reticular formation : 66 ; 3 -RRB- locus coeruleus : 20 -LRB- left -RRB- and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5 -RRB-	14225
14 -LRB- right -RRB-	14225
2 -RRB- reticular formation : 66 ; 3 -RRB- locus coeruleus : 20 -LRB- left -RRB- and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14237
reticular	14240
formation :	14250
formation	14250
66 ; 3 -RRB- locus coeruleus : 20 -LRB- left -RRB- and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14261
66	14261
3 -RRB- locus coeruleus : 20 -LRB- left -RRB- and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14265
locus	14268
coeruleus : 20 -LRB- left -RRB-	14274
coeruleus	14274
20	14285
left	14289
and 20 -LRB- right -RRB- ; 4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14295
and 20 -LRB- right -RRB-	14295
and 20	14295
right	14303
4 -RRB- vestibular nucleus : 26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14311
vestibular	14314
nucleus :	14325
nucleus	14325
26 -LRB- left -RRB- and 26 -LRB- right -RRB- ; 5	14334
26 -LRB- left -RRB- and 26 -LRB- right -RRB-	14334
26 -LRB- left -RRB-	14334
26 -LRB- right -RRB-	14348
raphe nucleus : 60	14363
raphe nucleus	14363
60	14378
Images of sections	14382
Images	14382
sections	14392
10x magnification using a camera -LRB- Leica DFC300 FX -RRB- attached to the microscope	14415
10x magnification	14415
a camera -LRB- Leica DFC300 FX -RRB- attached to the microscope	14439
a camera -LRB- Leica DFC300 FX -RRB-	14439
a camera	14439
Leica DFC300 FX	14449
the microscope	14478
Statistical Analysis The variables of the behavioral recovery study	14494
Statistical Analysis The variables	14494
Statistical Analysis	14494
The variables	14515
the behavioral recovery study	14532
categories -LRB- 31 -RRB-	14575
categories	14575
31	14587
Each climbing grid	14592
Each	14592
grid	14606
an increasing angle from the horizontal plane	14625
an increasing angle	14625
the horizontal plane	14650
a higher slope than the previous with each slope corresponding to 1 level of difficulty for the animals -LRB- Appendix 1 -RRB-	14686
a higher slope	14686
the previous with each slope corresponding to 1 level of difficulty for the animals -LRB- Appendix 1 -RRB-	14706
the previous	14706
each slope corresponding to 1 level of difficulty for the animals -LRB- Appendix 1 -RRB-	14724
each slope	14724
1 level of difficulty for the animals -LRB- Appendix 1 -RRB-	14752
1 level	14752
difficulty for the animals -LRB- Appendix 1 -RRB-	14763
difficulty	14763
the animals -LRB- Appendix 1 -RRB-	14778
the animals	14778
Appendix 1	14791
Scores to each ordinal category or slope and named them climbing levels -LRB- 1 < 2 < 3 < 4 -RRB-	14804
Scores to each ordinal category or slope and named them climbing levels	14804
Scores	14804
each ordinal category or slope	14814
each ordinal category	14814
slope	14839
them	14855
levels	14869
1 < 2 < 3 < 4	14877
1 < 2 < 3 <	14877
1 < 2 <	14877
1 <	14877
4	14889
ordinal categories	14911
nonparametric Kruskal-Wallis and Mann-Whitney U tests	14931
32	15007
We	15012
the former test	15020
the ability of the Non-T , OEG-transplanted , and Sham groups	15047
the ability	15047
the Non-T , OEG-transplanted , and Sham groups	15062
the 4 different climbing levels	15116
both SA and Chr stages	15151
both SA	15151
Chr stages	15163
Post hoc Conover-Inman for pairwise comparison	15175
Post hoc Conover-Inman	15175
pairwise comparison	15202
33	15232
Mann-Whitney U test	15237
the ability to succeed in the climbing test of Non-T versus OEGtransplanted groups at SA and Chr stages	15277
the climbing test of Non-T versus OEGtransplanted groups at SA and Chr stages	15303
the climbing test	15303
Non-T versus OEGtransplanted groups at SA and Chr stages	15324
Non-T	15324
OEGtransplanted groups at SA and Chr stages	15337
OEGtransplanted groups	15337
SA and Chr stages	15363
SA	15363
Chr stages	15370
Kruskal-Wallis test	15382
the significance of the time-dependent improvement	15423
the significance	15423
the time-dependent improvement	15443
function observed within the same group and between groups	15477
function	15477
the same group	15502
groups	15529
Statistical analyses of differences between groups in the number of regenerated neurons -LRB- total and nuclei by nuclei -RRB- and the extent of tissue degeneration at the injury site	15537
Statistical analyses	15537
differences between groups in the number of regenerated neurons -LRB- total and nuclei by nuclei -RRB- and the extent of tissue degeneration at the injury site	15561
differences	15561
groups in the number of regenerated neurons -LRB- total and nuclei by nuclei -RRB- and the extent of tissue degeneration at the injury site	15581
groups	15581
the number of regenerated neurons -LRB- total and nuclei by nuclei -RRB- and the extent of tissue degeneration at the injury site	15591
the number of regenerated neurons -LRB- total and nuclei by nuclei -RRB-	15591
the number	15591
regenerated neurons -LRB- total and nuclei by nuclei -RRB-	15605
regenerated neurons	15605
total and nuclei by nuclei	15626
total and nuclei	15626
nuclei	15646
the extent of tissue degeneration at the injury site	15658
the extent	15658
tissue degeneration at the injury site	15672
tissue degeneration	15672
the injury site	15695
nonparametric Kruskal-Wallis and Mann-Whitney U tests	15729
Nonparametric statistics	15784
the experimental groups	15827
fewer than 10 animals	15855
Data	15878
the mean T SEM	15900
all cases	15919
differences	15930
p	15973
Linear regression analysis	15983
the correlation between functional recovery and the number of neurons	16031
the correlation between functional recovery	16031
the correlation	16031
functional recovery	16055
the number of neurons	16079
the number	16079
neurons	16093
axons	16114
individual animals	16125
an estimation of the temporary progression of the functional recovery per rat	16149
an estimation	16149
the temporary progression of the functional recovery per rat	16166
the temporary progression	16166
the functional recovery per rat	16195
the functional recovery	16195
rat	16223
a score for each animal	16228
a score	16228
each animal	16240
the level achieved in the climbing test at each month during the testing period	16278
the level	16278
the climbing test at each month during the testing period	16300
the climbing test	16300
each month during the testing period	16321
each month	16321
the testing period	16339
These scores	16359
linear regression	16396
the number of regenerated neurons	16419
the number	16419
regenerated neurons	16433
individual animals	16458
RESULTS	16479
Brainstem Neurons Traced in Transplanted and Nontransplanted Animals	16494
Brainstem Neurons Traced	16494
Transplanted and Nontransplanted Animals	16522
1	16571
Appearance of the surgical field during different phases of the procedure .	16574
Appearance	16574
the surgical field during different phases	16588
the surgical field	16588
different phases	16614
the procedure	16634
-LRB- A -RRB- After spinal cord transection , both stumps	16649
-LRB- A -RRB-	16649
spinal cord transection	16659
stumps	16689
completeness of the lesion	16718
completeness	16718
the lesion	16734
-LRB- B -RRB- Spinal cord stumps	16746
-LRB- B -RRB- Spinal cord	16746
B	16747
the vertebral channel apposing one another	16791
the vertebral channel	16791
one another	16822
-LRB- C-F -RRB- Lesion region during the second surgery -LRB- access to the spinal cord for transplantation -RRB- .	16835
-LRB- C-F -RRB-	16835
Lesion region during the second surgery -LRB- access to the spinal cord for transplantation -RRB-	16841
Lesion region	16841
the second surgery -LRB- access to the spinal cord for transplantation -RRB-	16862
the second surgery	16862
access to the spinal cord for transplantation	16882
access	16882
the spinal cord for transplantation	16892
the spinal cord	16892
transplantation	16912
-LRB- C -RRB- The resin bridge -LRB- arrow -RRB-	16930
-LRB- C -RRB- The resin bridge	16930
-LRB- C -RRB-	16930
The resin bridge	16934
arrow	16952
the spinous processes and laminae of adjacent intact vertebrae	16979
the spinous processes and laminae	16979
adjacent intact vertebrae	17016
bridge removal	17053
a dense layer of connective tissue -LRB- arrowheads -RRB-	17069
a dense layer	17069
connective tissue -LRB- arrowheads -RRB-	17086
connective tissue	17086
arrowheads	17105
the underlying spinal cord -LRB- arrow -RRB-	17139
the underlying spinal cord	17139
arrow	17167
-LRB- E -RRB- Dorsal aspect of both spinal cord stumps 4 months after complete transection .	17175
-LRB- E -RRB-	17175
Dorsal aspect of both spinal cord stumps	17179
Dorsal aspect	17179
both spinal cord stumps	17196
4 months after complete transection	17220
4 months	17220
complete transection	17235
-LRB- F -RRB- Transplantation of olfactory bulb ensheathing glia -LRB- OB-OEG -RRB- using a glass microneedle -LRB- arrow -RRB- .	17257
-LRB- F -RRB- Transplantation of olfactory bulb	17257
-LRB- F -RRB-	17257
olfactory bulb	17280
glia -LRB- OB-OEG -RRB- using a glass microneedle -LRB- arrow -RRB-	17307
glia -LRB- OB-OEG -RRB-	17307
glia	17307
OB-OEG	17313
a glass microneedle	17327
arrow	17348
Inset : a detail of an OB-OEG culture used for transplantation and immunolabeled with anti-p75 .	17356
Inset	17356
a detail of an OB-OEG culture used for transplantation and immunolabeled with anti-p75	17363
a detail	17363
an OB-OEG culture used for transplantation and immunolabeled with anti-p75	17375
an OB-OEG culture	17375
transplantation	17402
anti-p75	17441
Arrows in -LRB- A -RRB- , -LRB- B -RRB- , and -LRB- E -RRB-	17451
Arrows	17451
-LRB- A -RRB- , -LRB- B -RRB- , and -LRB- E -RRB-	17461
-LRB- A -RRB-	17461
-LRB- B -RRB-	17466
-LRB- E -RRB-	17475
the transection sites	17488
FIGURE 2 .	17512
FIGURE	17512
2	17519
Video frames of a paraplegic rat	17522
Video frames	17522
a paraplegic rat	17538
olfactory bulb ensheathing glia at the chronic stage	17573
olfactory bulb ensheathing glia	17573
the chronic stage	17608
the third	17637
level , 5 months after transplantation	17656
level	17656
5 months after transplantation	17663
5 months	17663
transplantation	17678
Detail of the hindlimb movement	17695
Detail	17695
the hindlimb movement	17705
this rat	17742
its weight	17760
its body to reach the horizontal platform	17783
the horizontal platform	17801
The video of this animal	17826
The video	17826
this animal	17839
part of Video , Supplemental Digital Content 1 , http://links.lww.com/NEN/A62	17854
part	17854
Video , Supplemental Digital Content 1 , http://links.lww.com/NEN/A62	17862
Video , Supplemental Digital Content 1	17862
http://links.lww.com/NEN/A62	17901
FIGURE 3 .	17932
FIGURE	17932
3	17939
Functional recovery of paraplegic rats	17942
Functional recovery	17942
paraplegic rats	17965
olfactory bulb ensheathing glia transplantation at subacute	17987
olfactory bulb	17987
glia transplantation	18014
subacute	18038
SA	18048
chronic -LRB- Chr -RRB-	18056
chronic	18056
Chr	18065
stages	18070
-LRB- A , B -RRB- Levels	18078
the climbing test by -LRB- A -RRB- nontransplanted -LRB- Non-T -RRB- and SA , and by -LRB- B -RRB- Non-T and Chr rats at 3 , 5 , and 7 months postgrafting	18104
the climbing test by -LRB- A -RRB- nontransplanted -LRB- Non-T -RRB- and SA , and by -LRB- B -RRB- Non-T	18104
the climbing test	18104
-LRB- A -RRB- nontransplanted -LRB- Non-T -RRB- and SA	18125
-LRB- A -RRB- nontransplanted -LRB- Non-T -RRB-	18125
-LRB- A -RRB- nontransplanted	18125
-LRB- A -RRB-	18125
Non-T	18146
SA	18157
-LRB- B -RRB- Non-T	18168
B	18169
Chr rats at 3 , 5 , and 7 months postgrafting	18182
Chr rats	18182
3 , 5 , and 7 months	18194
3	18194
5	18197
7 months	18204
rats	18240
a functional recovery significantly higher	18252
a functional recovery	18252
that of Non-T -LRB- SA , p G 0.001 ; Chr , p = 0.001 -RRB-	18300
that	18300
Non-T -LRB- SA , p G 0.001 ; Chr , p = 0.001 -RRB-	18308
Non-T	18308
SA , p G 0.001 ; Chr , p = 0.001	18315
SA	18315
p G 0.001 ; Chr , p = 0.001	18319
p G 0.001	18319
p G	18319
0.001	18323
Chr , p = 0.001	18330
Chr	18330
p = 0.001	18335
p	18335
0.001	18339
Differences	18347
Month 6	18390
SA rats -LRB- Month 6 , p = 0.029 ; Months 7 and 8 , p = 0.020 -RRB-	18401
SA rats	18401
Month 6 , p = 0.029 ; Months 7 and 8 , p = 0.020	18410
Month 6	18410
p = 0.029 ; Months 7 and 8 , p = 0.020	18419
p = 0.029	18419
p	18419
0.029	18423
Months 7 and 8 , p = 0.020	18430
Months 7 and 8	18430
p = 0.020	18446
p	18446
0.020	18450
Month 7	18466
Chr -LRB- p = 0.045 -RRB-	18477
Chr	18477
p	18482
0.045	18486
There	18494
no differences between SA and Chr groups -LRB- compare -LSB- A -RSB- and -LSB- B -RSB- -RRB-	18505
no differences	18505
SA and Chr groups -LRB- compare -LSB- A -RSB- and -LSB- B -RSB- -RRB-	18528
SA and Chr groups	18528
SA	18528
Chr groups	18535
A -RSB- and -LSB- B -RSB-	18556
A -RSB-	18556
-LSB- B -RSB-	18563
-LRB- C -RRB- Progression of the functional outcome in all groups from the first month postlesion until the end of the survival period -LRB- Month 12 -RRB- .	18569
Progression	18573
the functional outcome in all groups	18588
the functional outcome	18588
all groups	18614
the first month postlesion	18630
the end of the survival period -LRB- Month 12 -RRB-	18663
the end	18663
the survival period -LRB- Month 12 -RRB-	18674
the survival period	18674
Month 12	18695
Each point	18706
the percentage of functional recovery	18728
the percentage	18728
functional recovery	18746
animals of each group	18779
animals	18779
each group	18790
lines	18809
the periods used to compare the outcome of Non-T versus SA -LRB- long dash -RRB- and Non-T versus Chr animals -LRB- short dash -RRB- from the first to the eighth month postgrafting	18820
the periods	18820
the outcome of Non-T versus SA -LRB- long dash -RRB- and Non-T versus Chr animals -LRB- short dash -RRB-	18848
the outcome	18848
Non-T versus SA -LRB- long dash -RRB- and Non-T versus Chr animals -LRB- short dash -RRB-	18863
Non-T versus SA -LRB- long dash -RRB-	18863
Non-T	18863
SA -LRB- long dash -RRB-	18876
SA	18876
long dash	18880
Non-T versus Chr animals -LRB- short dash -RRB-	18895
Non-T	18895
Chr animals -LRB- short dash -RRB-	18908
Chr animals	18908
short dash	18921
the first	18938
the eighth month postgrafting	18951
The Non-T animals -LRB- gray rhombi -RRB-	18982
The Non-T animals	18982
gray rhombi	19001
a slight but insignificant recovery	19021
Chr and SA groups	19075
Non-T animals	19104
The SA group -LRB- black circles -RRB- and Chr -LRB- black triangles -RRB-	19119
The SA group -LRB- black circles -RRB-	19119
The SA group	19119
black circles	19133
Chr -LRB- black triangles -RRB-	19152
Chr	19152
black triangles	19157
2 months	19192
transplantation	19207
3 and 6 months postlesion , respectively	19224
3 and 6 months postlesion	19224
3 and 6 months	19224
postlesion	19239
Improvement of SA and Chr rats	19266
Improvement	19266
SA and Chr rats	19281
SA	19281
Chr rats	19288
the second month	19310
the fifth -LRB- p = 0.004 -RRB- and fourth months -LRB- p = 0.021 -RRB-	19360
the fifth	19360
p	19371
0.004	19375
fourth months	19386
p	19401
0.021	19405
FIGURE 4 .	19428
FIGURE	19428
4	19435
Transection sites of olfactory bulb ensheathing	19438
Transection sites	19438
olfactory bulb ensheathing	19459
nontransplanted -LRB- Non-T -RRB- spinal cords	19503
Non-T	19520
12 months	19540
lesion	19556
Representative macroscopic images from subacute -LRB- SA -RRB- -LRB- A -RRB- and chronic -LRB- Chr -RRB- -LRB- B -RRB- transplanted spinal cords and from a Non-T spinal cord -LRB- C -RRB- .	19564
Representative macroscopic images	19564
subacute -LRB- SA -RRB- -LRB- A -RRB- and chronic -LRB- Chr -RRB- -LRB- B -RRB- transplanted spinal cords	19603
subacute -LRB- SA -RRB- -LRB- A -RRB-	19603
subacute -LRB- SA -RRB-	19603
subacute	19603
SA	19613
A	19618
chronic -LRB- Chr -RRB- -LRB- B -RRB- transplanted spinal cords	19625
chronic -LRB- Chr -RRB- -LRB- B -RRB-	19625
chronic -LRB- Chr -RRB-	19625
B	19640
spinal cords	19656
a Non-T spinal cord -LRB- C -RRB-	19678
a Non-T spinal cord	19678
C	19699
Rostral and caudal stumps in all transplanted cords	19703
Rostral and caudal stumps	19703
all transplanted cords	19732
white opaque tissue -LRB- A , B -RRB-	19771
white opaque tissue	19771
A , B	19792
A	19792
B	19795
cord stumps in Non-T rats	19799
cord stumps	19799
Non-T rats	19814
a translucent membrane -LRB- C -RRB-	19840
a translucent membrane	19840
C	19864
FIGURE 5 .	19869
FIGURE	19869
5	19876
Longitudinal spinal cord sections showing areas used for quantification of glial fibrillary acidic protein -LRB- GFAP -RRB- - negative tissue at the injury site .	19879
Longitudinal spinal cord sections showing areas used for quantification of glial fibrillary acidic protein -LRB- GFAP -RRB-	19879
Longitudinal spinal cord sections	19879
areas used for quantification of glial fibrillary acidic protein -LRB- GFAP -RRB-	19921
areas	19921
quantification of glial fibrillary acidic protein -LRB- GFAP -RRB-	19936
quantification	19936
glial fibrillary acidic protein -LRB- GFAP -RRB-	19954
glial fibrillary acidic protein	19954
GFAP	19987
negative tissue at the injury site	19993
negative tissue	19993
the injury site	20012
Sections of nontransplanted -LRB- A -RRB- and transplanted -LRB- B -RRB- spinal cords immunolabeled with anti-GFAP .	20029
Sections of nontransplanted -LRB- A -RRB- and transplanted -LRB- B -RRB-	20029
Sections	20029
nontransplanted -LRB- A -RRB- and transplanted -LRB- B -RRB-	20041
nontransplanted -LRB- A -RRB-	20041
transplanted -LRB- B -RRB-	20065
transplanted	20065
B	20079
spinal cords immunolabeled with anti-GFAP	20082
spinal cords	20082
anti-GFAP	20114
Encircled lines	20125
both GFAP-negative fibrous scar -LRB- arrows -RRB- and cysts -LRB- without arrows -RRB-	20151
GFAP-negative fibrous scar -LRB- arrows -RRB-	20156
GFAP-negative fibrous scar	20156
arrows	20184
cysts -LRB- without arrows -RRB-	20196
cysts	20196
arrows	20211
The widths of the cords	20220
The widths	20220
the cords	20234
these sections -LRB- horizontal lines in -LSB- A -RSB- and -LSB- B -RSB- -RRB-	20266
these sections	20266
horizontal lines in -LSB- A -RSB- and -LSB- B -RSB-	20282
horizontal lines	20282
-LSB- A -RSB- and -LSB- B -RSB-	20302
Top , rostral ; bottom , caudal .	20316
Top , rostral	20316
Top	20316
rostral	20321
bottom , caudal	20330
bottom	20330
caudal	20338
FIGURE 6 .	20347
FIGURE	20347
6	20354
Brainstem coronal sections showing peroxidase-traced neurons in olfactory bulb ensheathing glia -LRB- OB-OEG -RRB- - transplanted -LRB- A , C , E , G , I -RRB- and nontransplanted -LRB- B , D , F , H , J -RRB- rats .	20357
Brainstem coronal sections	20357
peroxidase-traced neurons in olfactory bulb ensheathing glia -LRB- OB-OEG -RRB- - transplanted -LRB- A , C , E , G , I -RRB- and nontransplanted -LRB- B , D , F , H , J -RRB- rats	20392
peroxidase-traced neurons in olfactory bulb ensheathing glia -LRB- OB-OEG -RRB-	20392
peroxidase-traced neurons	20392
olfactory bulb ensheathing glia -LRB- OB-OEG -RRB-	20421
olfactory bulb ensheathing glia	20421
OB-OEG	20454
transplanted -LRB- A , C , E , G , I -RRB-	20462
transplanted	20462
A	20476
C , E , G	20479
I	20488
nontransplanted -LRB- B , D , F , H , J -RRB- rats	20495
B , D , F , H , J	20512
B	20512
D	20515
F	20518
H	20521
J	20524
-LRB- A , B -RRB- Reticular formation -LRB- RF -RRB- .	20533
-LRB- A , B -RRB- Reticular formation -LRB- RF -RRB-	20533
-LRB- A , B -RRB- Reticular formation	20533
A , B	20534
A	20534
B	20537
RF	20561
-LRB- C , D -RRB- Vestibular nucleus -LRB- VN -RRB- .	20566
-LRB- C , D -RRB- Vestibular nucleus -LRB- VN -RRB-	20566
-LRB- C , D -RRB- Vestibular nucleus	20566
VN	20593
-LRB- E , F -RRB-	20598
E , F	20599
E	20599
F	20602
coeruleus -LRB- LC -RRB-	20611
coeruleus	20611
LC	20622
-LRB- G , H -RRB-	20627
R	20641
-LRB- I , J -RRB- Red nucleus -LRB- RN -RRB- .	20645
-LRB- I , J -RRB- Red nucleus -LRB- RN -RRB-	20645
-LRB- I , J -RRB- Red nucleus	20645
I	20646
J	20649
RN	20665
Scale	20670
= -LRB- A-J -RRB- 50 µm	20680
= -LRB- A-J -RRB-	20680
50 µm	20688
Top , dorsal ; bottom , ventral .	20695
Top , dorsal	20695
Top	20695
dorsal	20700
bottom , ventral	20708
bottom	20708
ventral	20716
FIGURE 7 .	20726
FIGURE	20726
7	20733
Quantification of neurons regenerating axons beyond the injury region .	20736
Quantification of neurons	20736
Quantification	20736
neurons	20754
axons	20775
the injury region	20788
A-E	20808
Histograms	20813
the number of peroxidase-traced neurons in nontransplanted -LRB- Non-T -RRB-	20829
the number	20829
peroxidase-traced neurons in nontransplanted -LRB- Non-T -RRB-	20843
peroxidase-traced neurons	20843
nontransplanted -LRB- Non-T -RRB-	20872
nontransplanted	20872
Non-T	20889
subacute -LRB- SA -RRB- , chronic -LRB- Chr -RRB- , and sham groups	20897
subacute -LRB- SA -RRB- , chronic -LRB- Chr -RRB- ,	20897
subacute -LRB- SA -RRB-	20897
subacute	20897
SA	20907
chronic -LRB- Chr -RRB-	20912
sham groups	20931
raphe -LRB- A -RRB- , reticular formation -LRB- B -RRB- , vestibular nuclei -LRB- C -RRB- , locus coeruleus -LRB- D -RRB- , red nuclei -LRB- E -RRB-	20954
raphe -LRB- A -RRB-	20954
raphe	20954
A	20961
reticular formation -LRB- B -RRB- , vestibular nuclei -LRB- C -RRB- , locus coeruleus -LRB- D -RRB- , red nuclei -LRB- E -RRB-	20965
reticular formation -LRB- B -RRB-	20965
reticular formation	20965
B	20986
vestibular nuclei -LRB- C -RRB-	20990
vestibular nuclei	20990
C	21009
locus coeruleus -LRB- D -RRB-	21013
locus coeruleus	21013
D	21030
red nuclei -LRB- E -RRB-	21034
red nuclei	21034
E	21046
all nuclei -LRB- F -RRB-	21057
all nuclei	21057
F	21069
Black rhombi	21073
the number of cell bodies per animal	21096
the number	21096
cell bodies per animal	21110
cell bodies	21110
animal	21126
bars	21134
the average of cell bodies per group	21143
the average	21143
cell bodies per group	21158
cell bodies	21158
group	21174
The total number of traced neurons	21181
The total number	21181
traced neurons	21201
SA and Chr animals than that in Non-T and also when comparing per nuclei -LRB- except for raphe in SA rats -RRB- -LRB- p < 0.05 -RRB-	21244
SA	21244
Chr animals than that in Non-T and also when comparing per nuclei -LRB- except for raphe in SA rats -RRB- -LRB- p < 0.05 -RRB-	21251
Chr animals	21251
that	21268
Non-T	21276
nuclei -LRB- except for raphe in SA rats -RRB- -LRB- p < 0.05 -RRB-	21310
nuclei -LRB- except for raphe in SA rats -RRB-	21310
nuclei	21310
raphe in SA rats	21329
raphe	21329
SA rats	21338
p < 0.05	21348
p	21348
< 0.05	21350
<	21350
0.05	21352
There	21359
no significant differences between SA and Chr groups in any case	21370
no significant differences between SA	21370
no significant differences	21370
SA	21405
Chr groups in any case	21412
Chr groups	21412
any case	21426
All animals	21437
injury	21464
the following 2 surgeries -LRB- transplantation and tracer injection -RRB-	21481
the following 2 surgeries	21481
transplantation and tracer injection	21508
1 Non-T rat that died during the second surgery -LRB- DMEM injection -RRB-	21558
1 Non-T rat	21558
the second surgery -LRB- DMEM injection -RRB-	21587
the second surgery	21587
DMEM injection	21607
more Non-T rats	21626
1 , 1.5 , 2 , and 4 months	21650
1	21650
1.5	21653
2	21658
4 months	21665
the second surgery	21680
autonomic dysreflexia or unknown causes	21710
autonomic dysreflexia	21710
unknown causes	21735
One Non-T rat	21751
the study	21785
it	21803
autotomy of its hindlimb	21816
autotomy	21816
its hindlimb	21828
6 rats	21848
Non-T controls	21868
none of the OB-OEG-grafted rats	21896
none	21896
the OB-OEG-grafted rats	21904
any complication	21932
1 animal	21958
the Chr group	21972
the very end of the study -LRB- 11.5 months after injury -RRB-	21994
the very end	21994
the study -LRB- 11.5 months after injury -RRB-	22010
the study	22010
11.5 months after injury	22021
11.5 months	22021
injury	22039
OB-OEG Transplantation Improved Voluntary Hindlimb Movement All transplanted and Non-T SCI rats	22048
OB-OEG Transplantation	22048
Voluntary Hindlimb Movement All	22080
transplanted and Non-T SCI rats	22112
transplanted	22112
Non-T SCI rats	22129
flaccid hindlimb paralysis	22148
We	22176
the climbing ability of all animals	22195
the climbing ability	22195
all animals	22219
1 month	22231
lesion	22245
the whole period	22260
Non-T rats of either group -LRB- second surgery after 1 or 4 months -RRB-	22278
Non-T rats	22278
either group -LRB- second surgery after 1 or 4 months -RRB-	22292
either group	22292
second surgery after 1 or 4 months	22306
second surgery	22306
1 or 4 months	22327
any difference in performance -LRB- p = 0.794 and p = 0.770 , respectively -RRB-	22355
any difference	22355
performance -LRB- p = 0.794 and p = 0.770 , respectively -RRB-	22373
performance	22373
p = 0.794 and p = 0.770 , respectively	22386
p = 0.794	22386
p	22386
0.794	22390
p = 0.770 , respectively	22400
p	22400
= 0.770	22402
This	22426
agreement with previous studies	22437
agreement	22437
previous studies	22452
the absence of histological differences	22477
the absence	22477
histological differences	22492
culture medium injection -LRB- 10 -RRB-	22523
culture medium injection	22523
10	22549
addition	22557
this	22567
the second surgery and our injection protocol	22587
the second surgery	22587
our injection protocol	22610
the normal progression of tissue changes	22675
the normal progression	22675
tissue changes	22701
all paraplegic Non-T rats	22725
they	22785
a single group -LRB- n = 6 -RRB-	22809
a single group	22809
n	22825
6	22829
Rats from both SA and Chr groups	22833
Rats	22833
both SA and Chr groups	22843
both SA	22843
Chr groups	22855
Non-T rats	22877
the climbing test before transplantation	22891
the climbing test	22891
transplantation	22916
We	22933
the climbing behavior of OB-OEG-grafted and nongrafted rats from the first month postgrafting , which corresponds to the second month postlesion for the SA group and the fifth for the Chr group -LRB- Fig. 3C -RRB-	22954
the climbing behavior	22954
OB-OEG-grafted and nongrafted rats from the first month postgrafting , which corresponds to the second month postlesion for the SA group and the fifth for the Chr group -LRB- Fig. 3C -RRB-	22979
OB-OEG-grafted and nongrafted rats	22979
the first month postgrafting , which corresponds to the second month postlesion for the SA group and the fifth for the Chr group	23019
the first month postgrafting	23019
the second month postlesion for the SA group and the fifth for the Chr group	23070
the second month postlesion for the SA group	23070
the second month postlesion	23070
the SA group	23102
the fifth for the Chr group	23119
the Chr	23133
Fig. 3C	23148
Functional Recovery	23158
the Subacute Stage All	23196
SA-transplanted rats	23219
the	23264
test -LRB- Fig. 3A -RRB-	23277
test	23277
Fig. 3A	23283
There	23293
a significant functional improvement of SA group in the ability to climb compared with the Non-T group -LRB- p < 0.001 -RRB-	23303
a significant functional improvement	23303
SA group	23343
the ability to climb compared with the Non-T group -LRB- p < 0.001 -RRB-	23355
the Non-T group -LRB- p < 0.001 -RRB-	23390
the Non-T group	23390
p < 0.001	23407
p	23407
< 0.001	23409
<	23409
0.001	23411
The OB-OEG-grafted rats	23419
a progressive improvement	23450
abilities	23488
the second month after transplantation , differences between SA and Non-T rats became evident	23507
the second month	23507
transplantation , differences between SA and Non-T rats	23530
transplantation	23530
differences between SA and Non-T rats	23547
differences	23547
SA and Non-T rats	23567
this time	23604
2 -LRB- 40 % -RRB- of 5 SA rats	23615
2 -LRB- 40 % -RRB-	23615
2	23615
40 %	23618
5 SA rats	23626
Level 1	23645
a month later	23654
one of these rats	23669
one	23669
these rats	23676
Level 2 and a third reached Level 1	23702
Level 2	23702
a third reached Level 1	23714
a third	23714
Level 1	23730
5 months postgrafting	23742
5 months	23742
all SA rats	23765
the climbing test	23790
1 achieved Level 3 and 4 -LRB- 80 % -RRB-	23809
1	23809
Level 3 and 4 -LRB- 80 % -RRB-	23820
Level 3 and 4	23820
80 %	23835
Level 1	23848
comparison	23860
half of Non-T rats -LRB- 50 % -RRB-	23872
half	23872
Non-T rats -LRB- 50 % -RRB-	23880
Non-T rats	23880
50 %	23892
any	23915
level	23928
the remaining	23944
some spontaneous improvement	23968
the recovery of Non-T rats	23998
the recovery	23998
Non-T rats	24014
that of transplanted animals	24049
that	24049
transplanted animals	24057
Only 1 of 6 Non-T rats	24079
Only 1	24079
6 Non-T rats	24089
Level 1	24111
the second month postinjury	24122
the only rat that improved thereafter	24158
the only rat	24158
the fourth and fifth months	24203
another 2 rats	24246
the lowest climbing level	24270
no further improvement -LRB- Fig. 3A -RRB-	24306
no further improvement	24306
Fig. 3A	24330
comparison	24343
SA animals	24355
significantly better scores in the climbing test	24373
significantly better scores	24373
the climbing test	24404
function	24446
the fifth month	24461
7 months after OB-OEG transplantation	24481
7 months	24481
OB-OEG transplantation	24496
SA rats	24520
their maximum functional recovery	24536
4 of them -LRB- 80 % -RRB-	24571
4 of them	24571
4	24571
them	24576
80 %	24582
Level 3 and one achieved Level 2 -LRB- Fig. 3A -RRB-	24597
Level 3 and one	24597
Level 2 -LRB- Fig. 3A -RRB-	24622
Level 2	24622
Fig. 3A	24631
A monthly comparison of functional outcome	24641
A monthly comparison	24641
functional outcome	24665
significant differences between SA and Non-T groups from the sixth month	24691
significant differences between SA	24691
significant differences	24691
SA	24723
Non-T groups from the sixth month	24730
Non-T groups	24730
the sixth month	24748
transplantation	24770
the end of the experiment	24792
the end	24792
the experiment	24803
Conover-Inman	24819
hoc values were p = 0.0145 at the sixth month and p = 0.0095 at the seventh month	24838
hoc	24838
values	24842
p =	24854
0.0145	24858
the sixth month and p = 0.0095	24868
the sixth month and p	24868
0.0095	24892
the seventh month	24902
Mann-Whitney U test	24921
a significance of p	24953
a significance	24953
p	24971
0.029	24975
Month 6	24984
p	24996
0.020	25000
Month 7	25009
the fifth month postgrafting	25034
the climbing performance exhibited by OB-OEG transplanted rats	25064
the climbing performance	25064
OB-OEG transplanted rats	25102
the first -LRB- p = 0.004 -RRB- and second months -LRB- p = 0.042 -RRB-	25146
the first	25146
p	25157
0.004	25161
second months	25172
p	25187
0.042	25191
This time-dependent recovery	25199
the seventh month	25252
Climbing performance at the seventh month	25271
Climbing performance	25271
the seventh month	25295
that at first -LRB- p = 0.004 -RRB- , second -LRB- p = 0.006 -RRB- , and third and fourth months -LRB- p = 0.009 , both -RRB-	25343
that	25343
first -LRB- p = 0.004 -RRB- , second -LRB- p = 0.006 -RRB- , and third and fourth months -LRB- p = 0.009 , both -RRB-	25351
first -LRB- p = 0.004 -RRB-	25351
first	25351
p	25358
0.004	25362
second -LRB- p = 0.006 -RRB-	25370
second	25370
p	25378
0.006	25382
third and fourth months -LRB- p = 0.009 , both -RRB-	25394
third and fourth months	25394
p = 0.009 , both	25419
p = 0.009	25419
p	25419
0.009	25423
comparison	25440
Non-T animals	25452
their climbing abilities	25482
time	25512
the spontaneous outcome exhibited by some of them	25522
the spontaneous outcome	25522
some of them	25559
some	25559
them	25567
statistical significance	25585
Functional Recovery	25611
the Chronic Stage	25649
transplantation	25674
Chr rats	25691
the climbing test similar to Non-T rats	25711
the climbing test	25711
Non-T rats	25740
transplantation -LRB- 4 months after injury -RRB-	25762
transplantation	25762
4 months after injury	25779
4 months	25779
injury	25794
they	25803
function more	25818
Non-T rats -LRB- p = 0.002 -RRB-	25837
Non-T rats	25837
p	25849
0.002	25853
One Non-T and 2 Chr rats	25861
One Non-T	25861
2 Chr rats	25875
some spontaneous recovery	25893
the second surgery -LRB- 4 months postlesion -RRB-	25931
the second surgery	25931
4 months postlesion	25951
4 months	25951
postlesion	25960
the lowest climbing level -LRB- not shown -RRB-	25985
the lowest climbing level	25985
The functional capabilities of the 2 Chr rats showing some recovery	26024
The functional capabilities	26024
the 2 Chr rats showing some recovery	26055
the 2 Chr rats	26055
some recovery	26078
OB-OEG injection	26118
proper integration of the graft within the cord parenchyma	26147
proper integration	26147
the graft within the cord parenchyma	26169
the graft	26169
the cord parenchyma	26186
the transplantation	26226
a chronic SCI	26276
The Chr rats	26291
motor function	26313
Non-T rats -LRB- p = 0.002 -RRB-	26352
Non-T rats	26352
p	26364
0.002	26368
improvement	26380
progressive -LRB- p = 0.016 -RRB- -LRB- Fig. 3B -RRB-	26396
progressive -LRB- p = 0.016 -RRB-	26396
progressive	26396
p	26409
0.016	26413
Fig. 3B	26421
The Chr rats	26431
motor function 2 months -LRB- 6 postlesion -RRB-	26457
motor function 2 months	26457
motor function	26457
2 months	26472
6 postlesion	26482
this period	26515
3 rats	26528
Level 1	26544
a month later	26557
they	26572
Level 2 or 3	26593
All Chr rats	26607
at least Level	26639
1 at 4 months	26654
grafting	26674
the fifth month	26687
3 of 5 rats	26704
3	26704
5 rats	26709
Level 3 , 1	26725
Level 2 , and the other , Level 1	26745
Level 2	26745
the other , Level 1	26758
the other	26758
Level 1	26769
These animals	26778
their maximum functional recovery	26799
the seventh month	26839
this	26862
the maximum climbing performance achieved by Non-T rats -LRB- Conover-Inman , p = 0.0299 ; Mann-Whitney U test , p = 0.045 -RRB-	26900
the maximum	26900
performance achieved by Non-T rats -LRB- Conover-Inman , p = 0.0299 ; Mann-Whitney U test , p = 0.045 -RRB-	26921
performance	26921
Non-T rats -LRB- Conover-Inman , p = 0.0299 ; Mann-Whitney U test , p = 0.045 -RRB-	26945
Non-T rats	26945
Conover-Inman , p = 0.0299 ; Mann-Whitney U test , p = 0.045	26957
Conover-Inman	26957
p = 0.0299 ; Mann-Whitney U test , p = 0.045	26972
p = 0.0299	26972
p	26972
0.0299	26976
Mann-Whitney U test , p = 0.045	26984
Mann-Whitney U test	26984
p = 0.045	27005
p	27005
0.045	27009
The recovery level of the Chr rats	27017
The recovery level	27017
the Chr rats	27039
4 months postgrafting than at 1 -LRB- p = 0.021 -RRB- and 2 months -LRB- p = 0.033 -RRB-	27066
4 months	27066
at 1 -LRB- p = 0.021 -RRB- and 2 months -LRB- p = 0.033 -RRB-	27093
at 1 -LRB- p = 0.021 -RRB-	27093
at 1	27093
p	27099
0.021	27103
2 months -LRB- p = 0.033 -RRB-	27114
p	27124
0.033	27128
These differences	27136
the seventh month -LRB- p = 0.013 vs Month 1 ; p = 0.016 vs Month 2 -RRB- -LRB- Fig. 3C -RRB-	27200
the seventh month -LRB- p = 0.013 vs Month 1 ; p = 0.016 vs Month 2 -RRB-	27200
the seventh month	27200
p = 0.013 vs Month 1 ; p = 0.016 vs Month 2	27219
p	27219
= 0.013 vs Month 1 ; p = 0.016 vs Month 2	27221
= 0.013 vs Month 1	27221
= 0.013	27221
Month 1	27232
p = 0.016 vs Month 2	27241
p = 0.016	27241
p	27241
0.016	27245
Month 2	27254
Fig. 3C	27264
Comparison	27274
Groups	27306
Subacute	27316
Chronic Stages	27329
the transplantation delay -LRB- 1 or 4 months -RRB-	27352
the transplantation delay	27352
1 or 4 months	27379
SA and Chr rats	27395
recovering motor function	27419
the second month postgrafting	27451
the following months	27511
There	27533
no differences in climbing performance at any month postgrafting -LRB- p = 0.1-0.635 -RRB- reaching the maximum at the seventh month	27544
no differences	27544
performance at any month postgrafting	27571
performance	27571
any month postgrafting	27586
p = 0.1-0.635	27610
p	27610
= 0.1-0.635	27612
the maximum	27634
the seventh month	27649
All transplanted rats	27668
hindlimb movement , plantar placement of the paws , and the body weight support necessary to succeed in the test independent of the stage of transplantation -LRB- n = 10 -RRB-	27697
hindlimb movement	27697
plantar placement of the paws	27716
plantar placement	27716
the paws	27737
the body weight support necessary to succeed in the test independent of the stage of transplantation -LRB- n = 10 -RRB-	27751
the body weight support	27751
the test independent of the stage of transplantation -LRB- n = 10 -RRB-	27799
the test independent	27799
the stage of transplantation -LRB- n = 10 -RRB-	27823
the stage	27823
transplantation -LRB- n = 10 -RRB-	27836
transplantation	27836
n	27853
10	27857
the end of the study	27865
the end	27865
the study	27876
the transplantation delay	27901
70 % of all OEG-grafted rats	27928
70 %	27928
all OEG-grafted rats	27935
the platform by climbing from Level 3 , 10 % climbing from Level 2 , and 20 % from Level 1	27975
the platform by climbing from Level 3	27975
the platform	27975
Level 3	28005
10 % climbing from Level 2	28014
10 %	28014
Level 2	28032
20 % from Level 1	28045
20 %	28045
Level 1	28054
All -LRB- 100 % -RRB- rats from SA and Chr groups	28063
All -LRB- 100 % -RRB- rats	28063
100 %	28068
SA and Chr groups	28084
SA	28084
Chr groups	28091
the climbing test	28119
the fifth and fourth months	28140
these postgrafting testing periods	28186
the climbing performance	28222
the previous test period -LRB- p = 0.004 and p = 0.021 , respectively -RRB-	28270
the previous test period	28270
p = 0.004 and p = 0.021 , respectively	28296
p = 0.004	28296
p	28296
0.004	28300
p = 0.021 , respectively	28310
p	28310
= 0.021	28312
Tissue Repair	28336
SCI by OB-OEG Grafts Evaluation of Transplantation Effects on Scarring Macroscopically , in all transplanted rats	28356
SCI	28356
OB-OEG Grafts Evaluation of Transplantation Effects on Scarring Macroscopically , in all transplanted rats	28363
OB-OEG Grafts Evaluation	28363
Transplantation Effects on Scarring Macroscopically , in all transplanted rats	28391
Transplantation Effects	28391
Macroscopically , in all transplanted rats	28427
Macroscopically	28427
all transplanted rats	28447
there	28470
a white and opaque tissue at the injury site bridging both cord stumps -LRB- Figs. 4A , B -RRB- , suggesting some quantitative differences in the tissue	28480
a white and opaque tissue	28480
the injury site bridging both cord stumps -LRB- Figs. 4A , B -RRB- , suggesting some quantitative differences in the tissue	28509
the injury site	28509
cord stumps -LRB- Figs. 4A , B -RRB- , suggesting some quantitative differences in the tissue	28539
cord stumps -LRB- Figs. 4A , B -RRB-	28539
cord stumps	28539
Figs. 4A , B	28552
Figs. 4A	28552
B	28562
some quantitative differences in the tissue	28577
some quantitative differences	28577
the tissue	28610
This property	28622
Non-T animals , in which the bridge region appeared thin and translucent -LRB- Fig. 4C -RRB-	28656
Non-T animals	28656
the bridge region	28680
Fig. 4C	28729
microscopy	28742
all injured spinal cords	28754
an interruption of GFAP immunolabeling	28786
an interruption	28786
GFAP immunolabeling	28805
the lesion over the entire spinal cord width	28828
the lesion	28828
the entire spinal cord width	28844
transection	28890
Fig. 5	28916
The Hoechst	28925
OB-OEG	28966
cells of the host	28976
cells	28976
the host	28985
spinal cords -LRB- Figure , Supplemental Digital Content 3 , http://links.lww.com/NEN/A64 -RRB-	28994
spinal cords	28994
Figure , Supplemental Digital Content 3 , http://links.lww.com/NEN/A64	29008
Figure	29008
Supplemental Digital Content 3	29016
http://links.lww.com/NEN/A64	29048
The distribution of OB-OEG within the spinal cord	29079
The distribution	29079
OB-OEG within the spinal cord	29099
OB-OEG	29099
the spinal cord	29113
the same	29133
transplantation at the acute stage -LRB- 3 , 4 -RRB-	29172
transplantation	29172
the acute stage -LRB- 3 , 4 -RRB-	29191
the acute stage	29191
3	29208
4	29211
OB-OEG	29224
the injection sites	29245
the glial and fibrous scars	29277
They	29306
reactive astrocytes	29329
the inhibitory fibrous scar	29354
their migration	29397
Figure , Supplemental Digital Content 3 , http://links.lww.com/NEN/A64	29414
Figure	29414
Supplemental Digital Content 3	29422
http://links.lww.com/NEN/A64	29454
the effect of OB-OEG	29497
the effect	29497
OB-OEG	29511
tissue repair and scarring	29521
we	29549
the volume of GFAP-negative tissue -LRB- fibrous scar -RRB-	29563
the volume	29563
GFAP-negative tissue -LRB- fibrous scar -RRB-	29577
GFAP-negative tissue	29577
fibrous scar	29599
cavities	29618
GFAP-positive stumps -LRB- Fig. 5 -RRB-	29642
GFAP-positive stumps	29642
Fig. 5	29664
Both volumes -LRB- fibrous scar and cavities -RRB-	29673
Both volumes	29673
fibrous scar and cavities	29687
fibrous scar	29687
cavities	29704
they	29742
a measure of trauma-induced degeneration	29755
a measure	29755
trauma-induced degeneration	29768
The mean volume of GFAP-negative tissue	29797
The mean volume	29797
GFAP-negative tissue	29816
larger in the Non-T group -LRB- 4.93 ± 0.96 mm3 -RRB- as compared with SA -LRB- 2.42 ± 0.34 mm3 , p = 0.009 -RRB- and Chr -LRB- 2.14 ± 0.57 mm3 , p = 0.05 for Chr -RRB- groups -LRB- Fig. 5 -RRB-	29841
larger in the Non-T group -LRB- 4.93 ± 0.96 mm3 -RRB- as compared with SA -LRB- 2.42 ± 0.34 mm3 , p = 0.009 -RRB- and Chr -LRB- 2.14 ± 0.57 mm3 , p = 0.05 for Chr -RRB- groups	29841
the Non-T group	29851
4.93 ± 0.96 mm3	29868
4.93 ± 0.96	29868
4.93	29868
0.96	29875
mm3	29880
SA -LRB- 2.42 ± 0.34 mm3 , p = 0.009 -RRB- and Chr -LRB- 2.14 ± 0.57 mm3 , p = 0.05 for Chr -RRB-	29902
SA	29902
2.42 ± 0.34 mm3 , p	29906
2.42 ± 0.34 mm3	29906
2.42	29906
0.34 mm3	29913
p	29923
0.009	29927
Chr	29938
2.14 ± 0.57 mm3 , p	29943
2.14 ± 0.57 mm3	29943
2.14	29943
0.57 mm3	29950
p	29960
0.05	29964
Chr	29973
Fig. 5	29986
the amount of fibrosis and necrosis	30006
the amount	30006
fibrosis and necrosis	30020
nongrafted spinal cords compared with grafted ones	30056
nongrafted spinal cords	30056
grafted ones	30094
This	30108
OB-OEG	30128
the formation of new tissue and better stump healing	30143
the formation	30143
new tissue and better stump healing	30160
new tissue	30160
better stump healing	30175
the decrease of tissue loss	30203
the decrease	30203
tissue loss	30219
the case of SA rats	30234
the case	30234
SA rats	30246
spinal cord repair	30271
the lesion site	30293
There	30310
no significant differences in the values between rats transplanted at SA and Chr stages -LRB- p = 0.624 -RRB-	30321
no significant differences	30321
the values between rats transplanted at SA and Chr stages -LRB- p = 0.624 -RRB-	30351
the values	30351
rats transplanted at SA and Chr stages	30370
rats	30370
SA and Chr stages	30391
SA	30391
Chr stages	30398
p	30410
0.624	30414
the efficacy of OB-OEG in spinal cord preservation at the injury	30428
the efficacy	30428
OB-OEG in spinal cord preservation at the injury	30444
OB-OEG	30444
spinal cord preservation at the injury	30454
spinal cord preservation	30454
the injury	30482
the timing of transplantation	30520
the timing	30520
transplantation	30534
The volume of GFAP-negative fibrosis and cysts	30551
The volume	30551
GFAP-negative fibrosis and cysts	30565
the maximum functional levels	30623
the maximum	30623
the climbing test -LRB- r = -0.800 ; p < 0.001 -RRB-	30656
the climbing test	30656
r = -0.800 ; p < 0.001	30675
r = -0.800 ; p <	30675
r = -0.800	30675
r	30675
-0.800	30679
p <	30687
p	30687
<	30689
0.001	30691
better tissue preservation in OB-OEGYgrafted rats	30710
better tissue preservation	30710
OB-OEGYgrafted rats	30740
axonal regeneration	30775
the lesion	30802
OB-OEG	30814
Axonal Regeneration of Brainstem Neurons Beyond the Scar Axons	30830
Axonal Regeneration	30830
Brainstem Neurons Beyond the Scar Axons	30853
Brainstem Neurons	30853
the Scar Axons	30878
the injury site	30909
more	30940
the scar than axons elongating straight beyond	30958
the scar	30958
axons elongating straight beyond	30972
axons	30972
nontreated animals	31020
more fibers within the scar than animals showing axonal regeneration	31048
more fibers	31048
the scar than animals showing axonal regeneration	31067
the scar	31067
animals showing axonal regeneration	31081
animals	31081
axonal regeneration	31097
this	31127
NFL labeling	31138
the scar not a very accurate method for quantification of axonal regeneration	31154
the scar	31154
a very accurate method for quantification of axonal regeneration	31167
a very accurate method	31167
quantification of axonal regeneration	31194
quantification	31194
axonal regeneration	31212
we	31233
an estimate of the number of fibers invading the injury region	31251
an estimate	31251
the number of fibers invading the injury region	31266
the number	31266
fibers invading the injury region	31280
fibers	31280
the injury region	31296
We	31315
NFL-immunolabeled axons	31327
the scars	31360
both grafted and Non-T spinal cords	31373
both grafted	31373
both	31373
Non-T spinal cords	31390
There	31410
no group differences in the number of pixels representing NFLpositive sprouts within the scar tissue of SA , Chr , and Non-T rats -LRB- p = 0.462 -RRB-	31421
no group differences	31421
the number of pixels representing NFLpositive sprouts within the scar tissue of SA , Chr , and Non-T rats -LRB- p = 0.462 -RRB-	31445
the number	31445
pixels representing NFLpositive sprouts within the scar tissue of SA , Chr , and Non-T rats -LRB- p = 0.462 -RRB-	31459
pixels	31459
NFLpositive sprouts	31479
the scar tissue of SA , Chr , and Non-T rats -LRB- p = 0.462 -RRB-	31506
the scar tissue	31506
SA , Chr , and Non-T rats -LRB- p = 0.462 -RRB-	31525
SA	31525
Chr	31529
Non-T rats	31538
p	31550
0.462	31554
axonal regeneration	31574
the lesion	31601
we	31613
the retrograde tracer	31625
0.5 cm	31650
the rostral border of the caudal stump	31662
the rostral border	31662
the caudal stump	31684
We	31702
no inadvertent leakage or spread of the tracer	31714
no inadvertent leakage or spread	31714
the tracer	31750
the lesion	31776
the spinal cords of 3 animals	31800
the spinal cords	31800
3 animals	31820
each group	31835
The retrograde tracer	31847
the injury site or the edge of the caudal stump	31883
the injury site	31883
the edge of the caudal stump	31902
the edge	31902
the caudal stump	31914
the caudal cord -LRB- Figure , Supplemental Digital Content 2 , http://links.lww.com/NEN/A63 -RRB-	31952
the caudal cord	31952
Figure , Supplemental Digital Content 2 , http://links.lww.com/NEN/A63	31969
Figure	31969
Supplemental Digital Content 2	31977
http://links.lww.com/NEN/A63	32009
the tracer	32048
0.5	32075
the lesion	32084
only axons crossing the injury region , invading the caudal stump and growing at least 0.5 cm beyond	32096
only axons	32096
the injury region	32116
the caudal stump	32144
at least 0.5 cm	32173
the tracer	32210
all neurons containing peroxidase	32228
all neurons	32228
peroxidase	32251
neurons whose axons grew 0.5 cm or more far down into the caudal stump	32280
neurons	32280
axons	32294
0.5 cm	32305
the caudal stump	32334
Retrograde peroxidase-labeled neurons	32352
5 brainstem nuclei relevant for the initiation and modulation of locomotor patterns	32406
5 brainstem nuclei	32406
the initiation and modulation of locomotor patterns	32438
the initiation and modulation	32438
locomotor patterns	32471
All nuclei examined	32491
All nuclei	32491
horseradish peroxidase-labeled neurons -LRB- Fig. 6 -RRB-	32521
horseradish peroxidase-labeled neurons	32521
Fig. 6	32561
The mean total number of peroxidase-labeled neurons in the brainstem of sham rats	32570
The mean total number	32570
peroxidase-labeled neurons in the brainstem of sham rats	32595
peroxidase-labeled neurons	32595
the brainstem of sham rats	32625
the brainstem	32625
sham rats	32642
16,399 ± 609 -LRB- n = 3 -RRB-	32656
16,399 ± 609	32656
16,399	32656
609	32665
n	32670
3	32674
This value	32678
5,203 ± 1,116	32693
5,203	32693
1,116	32701
SA rats and 6,330 ± 1,176	32710
SA rats	32710
6,330 ± 1,176	32722
6,330	32722
1,176	32730
the Chr group	32739
The total number of neurons regenerating their axons beyond the lesion	32754
The total number	32754
neurons regenerating their axons beyond the lesion	32774
neurons	32774
their axons	32795
the lesion	32814
more than twice in OB-OEG-grafted animals -LRB- either SA or Chr -RRB- compared with Non-T rats -LRB- 2,198 ± 416 -RRB- -LRB- p < 0.018 -RRB- -LRB- Fig. 7 -RRB-	32829
more than twice	32829
OB-OEG-grafted animals -LRB- either SA or Chr -RRB- compared with Non-T rats -LRB- 2,198 ± 416 -RRB- -LRB- p < 0.018 -RRB- -LRB- Fig. 7 -RRB-	32848
OB-OEG-grafted animals -LRB- either SA or Chr -RRB-	32848
OB-OEG-grafted animals	32848
SA or Chr	32879
SA	32879
Chr	32885
Non-T rats -LRB- 2,198 ± 416 -RRB- -LRB- p < 0.018 -RRB-	32904
Non-T rats -LRB- 2,198 ± 416 -RRB-	32904
Non-T rats	32904
2,198 ± 416	32916
2,198 ±	32916
416	32924
p < 0.018	32930
p	32930
< 0.018	32932
<	32932
0.018	32934
Fig. 7	32942
Significance	32951
analysis	32981
individual nuclei : reticular formation -LRB- SA , p = 0.006 ; Chr , p = 0.011 -RRB- ; vestibular nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.019 -RRB- ; locus coeruleus -LRB- SA , p = 0.018 ; Chr , p = 0.033 -RRB- ; red nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.011 -RRB- ; and raphe -LRB- SA , p = 0.201 ; Chr , p = 0.019 -RRB-	33014
individual nuclei : reticular formation -LRB- SA , p = 0.006 ; Chr , p = 0.011 -RRB- ; vestibular nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.019 -RRB- ; locus coeruleus -LRB- SA , p = 0.018 ; Chr , p = 0.033 -RRB- ; red nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.011 -RRB-	33014
individual nuclei	33014
reticular formation -LRB- SA , p = 0.006 ; Chr , p = 0.011 -RRB- ; vestibular nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.019 -RRB- ; locus coeruleus -LRB- SA , p = 0.018 ; Chr , p = 0.033 -RRB- ; red nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.011	33033
reticular formation -LRB- SA , p = 0.006 ; Chr , p = 0.011 -RRB-	33033
reticular formation	33033
SA , p = 0.006 ; Chr , p = 0.011	33054
SA	33054
p = 0.006 ; Chr , p = 0.011	33058
p = 0.006	33058
p	33058
0.006	33062
Chr , p = 0.011	33069
Chr	33069
p = 0.011	33074
p	33074
0.011	33078
vestibular nucleus -LRB- SA , p = 0.018 ; Chr , p = 0.019 -RRB-	33086
vestibular nucleus	33086
SA , p = 0.018 ; Chr , p = 0.019	33106
SA	33106
p = 0.018 ; Chr , p = 0.019	33110
p = 0.018	33110
p	33110
0.018	33114
Chr , p = 0.019	33121
Chr	33121
p = 0.019	33126
p	33126
0.019	33130
locus coeruleus -LRB- SA , p = 0.018 ; Chr , p = 0.033 -RRB-	33138
locus coeruleus	33138
SA , p = 0.018 ; Chr , p = 0.033	33155
SA	33155
p = 0.018 ; Chr , p = 0.033	33159
p = 0.018	33159
p	33159
0.018	33163
Chr , p = 0.033	33170
Chr	33170
p = 0.033	33175
p	33175
0.033	33179
red nucleus -LRB- SA , p = 0.018	33187
red nucleus -LRB- SA , p	33187
0.018	33208
Chr , p = 0.011	33215
Chr	33215
p = 0.011	33220
p	33220
0.011	33224
raphe -LRB- SA , p = 0.201 ; Chr , p = 0.019 -RRB-	33236
raphe	33236
SA , p = 0.201 ; Chr , p = 0.019	33243
SA	33243
p = 0.201 ; Chr , p = 0.019	33247
p = 0.201	33247
p	33247
0.201	33251
Chr , p = 0.019	33258
Chr	33258
p = 0.019	33263
p	33263
0.019	33267
The only exception	33275
raphe nucleus of the SA group , in which the differences were not significant	33298
raphe nucleus	33298
the SA group , in which the differences were not significant	33315
the SA group	33315
the differences	33338
The Chr rats	33376
greater numbers of regenerating brainstem neurons in all nuclei than in SA rats	33399
greater numbers	33399
brainstem neurons	33431
all nuclei	33452
SA rats	33471
differences between the paradigms	33484
differences	33484
the paradigms	33504
The percentage of total traced neurons , per nuclei and experimental group , with respect to equivalent nuclei of sham animals -LRB- 100 % -RRB-	33540
The percentage	33540
total traced neurons , per nuclei and experimental group , with respect to equivalent nuclei of sham animals -LRB- 100 % -RRB-	33558
total	33558
neurons , per nuclei and experimental group ,	33571
neurons	33571
nuclei and experimental group	33584
nuclei	33584
experimental group	33595
respect	33620
equivalent nuclei of sham animals -LRB- 100 % -RRB-	33631
equivalent nuclei	33631
sham animals -LRB- 100 % -RRB-	33652
sham animals	33652
100 %	33666
38.6 % and 31.7 %	33676
Chr and SA	33695
Chr	33695
SA	33703
comparison	33724
13.4 % of neurons of the Non-T rats	33736
13.4 %	33736
neurons of the Non-T rats	33745
neurons	33745
the Non-T rats	33756
Raphe and red nuclei	33785
Raphe	33785
red nuclei	33795
the highest number of regenerating neurons in both SA and Chr groups	33816
the highest number	33816
regenerating neurons in both SA and Chr groups	33838
regenerating neurons	33838
both SA and Chr groups	33862
both SA	33862
Chr groups	33874
The SA rats	33886
63.4 % and 46.6 % of neurons traced in raphe and red nuclei	33902
63.4 % and 46.6 %	33902
neurons traced in raphe and red nuclei	33921
neurons	33921
raphe and red nuclei	33939
the Chr rats	33979
58.2 % and 46.9 %	33999
Non-T animals	34034
the raphe and red nuclei	34049
the raphe	34049
red nuclei	34063
more spontaneous regeneration	34081
other nuclei	34116
25.9 % neurons labeled in raphe and 28.9 % in the latter	34135
25.9 % neurons	34135
raphe and 28.9 %	34160
raphe	34160
28.9 %	34170
the latter	34179
The highest incidence of regenerating neurons after OB-OEG grafting -LRB- up to 8-fold -RRB-	34191
The highest incidence	34191
neurons	34229
OB-OEG grafting	34243
the locus coeruleus -LRB- 19 % in Chr and 13.8 % in SA compared with 2.4 % in Non-T -RRB-	34290
the locus coeruleus	34290
19 % in Chr and 13.8 % in SA compared with 2.4 % in Non-T	34311
19 %	34311
Chr and 13.8 % in SA	34318
Chr	34318
13.8 % in SA	34326
13.8 %	34326
SA	34335
2.4 % in Non-T	34352
2.4 %	34352
Non-T	34360
The percentage of peroxidase-labeled neurons in the reticular formation and vestibular nuclei of transplanted rats compared with sham animals	34368
The percentage	34368
peroxidase-labeled neurons in the reticular formation and vestibular nuclei of transplanted rats compared with sham animals	34386
peroxidase-labeled neurons in the reticular formation	34386
peroxidase-labeled neurons	34386
the reticular formation	34416
vestibular nuclei of transplanted rats compared with sham animals	34444
vestibular nuclei	34444
transplanted rats compared with sham animals	34465
transplanted rats	34465
sham animals	34497
30 % to 40 %	34514
that	34540
3 times	34549
the Non-T group -LRB- Table -RRB-	34570
the Non-T group	34570
Table	34587
summary	34598
the histological results	34607
axons from several brainstem nuclei that are relevant to motor function	34642
axons	34642
several brainstem nuclei that are relevant to motor function	34653
several brainstem nuclei	34653
motor function	34699
the scars	34733
the caudal stump	34764
The extent of axonal regeneration	34782
The extent	34782
axonal regeneration	34796
rats transplanted at SA and Chr phases , indicating that the repair efficacy of OB-OEG remained unaltered after delayed transplantation and was independent of the stage of the healing process	34831
rats	34831
SA and Chr phases	34852
SA	34852
Chr phases	34859
the repair efficacy of OB-OEG	34887
the repair efficacy	34887
OB-OEG	34910
delayed transplantation	34942
the stage of the healing process	34989
the stage	34989
the healing process	35002
brainstem neurons	35033
their capacity to respond positively to OB-OEG up to 4 months postlesion	35060
4 months postlesion	35113
there	35145
a window of at least 4 months in which OB-OEG could be applied without any apparent adverse effect	35155
a window	35155
at least 4 months	35167
OB-OEG	35194
any apparent adverse effect	35226
Functional Outcome	35255
the Extent of Axonal Regeneration and Tissue Preservation	35290
the Extent	35290
Axonal Regeneration and Tissue Preservation	35304
Axonal Regeneration	35304
Tissue Preservation	35328
The maximum climbing level achieved by each rat	35348
The maximum	35348
level achieved by each rat	35369
level	35369
each rat	35387
the total number of retrogradely labeled brainstem neurons -LRB- r = 0.733 ; p = 0.001 -RRB-	35427
the total number	35427
retrogradely labeled brainstem neurons -LRB- r = 0.733 ; p = 0.001 -RRB-	35447
retrogradely labeled brainstem neurons	35447
r = 0.733 ; p = 0.001	35487
r	35487
= 0.733 ; p = 0.001	35489
= 0.733	35489
p = 0.001	35498
p	35498
0.001	35502
There	35510
a correlation between climbing ability and the number of somata in each independent nucleus and in all nuclei analyzed -LRB- r = coefficients ranging from 0.784 to 0.641 ; p < 0.008 -RRB-	35525
a correlation	35525
ability and the number of somata	35556
ability	35556
the number of somata	35568
the number	35568
somata	35582
each independent nucleus	35592
all nuclei analyzed	35624
all nuclei	35624
r = coefficients ranging from 0.784 to 0.641 ; p < 0.008	35645
r = coefficients	35645
0.784 to 0.641 ; p < 0.008	35675
0.784 to 0.641	35675
p < 0.008	35691
p <	35691
p	35691
0.008	35695
the temporary progression of functional recovery per rat	35715
the temporary progression	35715
functional recovery per rat	35744
functional recovery	35744
rat	35768
a score	35773
animal	35798
the level	35816
each month	35835
8 months posttransplantation	35853
We	35883
this period	35895
there	35915
no further improvement after the seventh month	35925
no further improvement	35925
the seventh month	35954
The final score obtained for each rat in the performance in the climbing test	35973
The final score	35973
each rat in the performance in the climbing test	36002
each rat	36002
the performance in the climbing test	36014
the performance	36014
the climbing test	36033
the total number of labeled cell bodies -LRB- r = 0.897 ; p < 0.001 -RRB-	36072
the total number	36072
labeled cell bodies	36092
r = 0.897 ; p < 0.001	36113
r = 0.897 ; p <	36113
r = 0.897	36113
r	36113
0.897	36117
p <	36124
p	36124
<	36126
0.001	36128
the number of somata	36139
the number	36139
somata	36153
each nucleus -LRB- r = 0.899-0.847 ; p < 0.001 -RRB-	36163
each nucleus	36163
r = 0.899-0.847 ; p < 0.001	36177
r = 0.899-0.847 ; p <	36177
r = 0.899-0.847	36177
r	36177
0.899-0.847	36181
p <	36194
p	36194
<	36196
0.001	36198
These positive linear correlations	36206
the concept	36261
these brainstem neurons	36278
the functional improvement of the implanted rats	36317
the functional improvement	36317
the implanted rats	36347
addition	36370
there	36380
a linear negative correlation between the volume of GFAP-negative tissue -LRB- fibrosis and cavities -RRB- and the total number of traced brainstem neurons in both all -LRB- r = j0 .767 ; p < 0.001 -RRB- and each -LRB- r = 0.780-0.697 ; p < 0.002 -RRB- nuclei	36390
a linear negative correlation	36390
the volume of GFAP-negative tissue -LRB- fibrosis and cavities -RRB- and the total number of traced brainstem neurons in both all -LRB- r = j0 .767 ; p < 0.001 -RRB- and each -LRB- r = 0.780-0.697 ; p < 0.002 -RRB- nuclei	36428
the volume of GFAP-negative tissue -LRB- fibrosis and cavities -RRB-	36428
the volume	36428
GFAP-negative tissue -LRB- fibrosis and cavities -RRB-	36442
GFAP-negative tissue	36442
fibrosis and cavities	36464
the total number of traced brainstem neurons in both all -LRB- r = j0 .767 ; p < 0.001 -RRB- and each -LRB- r = 0.780-0.697 ; p < 0.002 -RRB- nuclei	36491
the total number	36491
traced brainstem neurons in both all -LRB- r = j0 .767 ; p < 0.001 -RRB- and each -LRB- r = 0.780-0.697 ; p < 0.002 -RRB- nuclei	36511
traced brainstem neurons	36511
both all -LRB- r = j0 .767 ; p < 0.001 -RRB- and each -LRB- r = 0.780-0.697 ; p < 0.002 -RRB- nuclei	36539
both all -LRB- r = j0 .767 ; p < 0.001 -RRB-	36539
both all	36539
r = j0 .767 ; p < 0.001	36549
r = j0 .767 ; p <	36549
r = j0 .767	36549
r = j0	36549
.767	36555
p <	36561
p	36561
<	36563
0.001	36565
each -LRB- r = 0.780-0.697 ; p < 0.002 -RRB- nuclei	36576
r = 0.780-0.697 ; p < 0.002	36582
r = 0.780-0.697 ; p <	36582
r = 0.780-0.697	36582
r	36582
0.780-0.697	36586
p <	36599
p	36599
<	36601
0.002	36603
This	36618
the smaller	36638
the degenerative events at the injury site , the greater axonal regeneration	36650
the degenerative events	36650
the injury site , the greater axonal regeneration	36677
the injury site	36677
the greater axonal regeneration	36694
our results	36745
a role of OB-OEG on tissue preservation	36765
a role	36765
OB-OEG on tissue preservation	36775
OB-OEG	36775
tissue preservation	36785
tissue formation	36812
the lesion zone	36832
that	36848
axonal regeneration	36868
it	36895
DISCUSSION The OB-OEG promoted both functional recovery of paraplegic rats and regeneration of supraspinal axons	36900
DISCUSSION	36900
The OB-OEG	36911
both functional recovery of paraplegic rats and regeneration of supraspinal axons	36931
functional recovery of paraplegic rats	36936
functional recovery	36936
paraplegic rats	36959
regeneration of supraspinal axons	36979
regeneration	36979
supraspinal axons	36995
the lesion in rats receiving a graft after 1 and 4 months after the complete lesion	37023
the lesion	37023
rats receiving a graft after 1 and 4 months after the complete lesion	37037
rats	37037
a graft	37052
1 and 4 months after the complete lesion	37066
1 and 4 months	37066
the complete lesion	37087
functional outcome after OB-OEG transplantation at 4 months postlesion	37120
functional outcome	37120
OB-OEG transplantation at 4 months postlesion	37145
OB-OEG transplantation	37145
4 months postlesion	37171
that at either subacute or acute -LRB- 4 -RRB- time points	37211
that	37211
either subacute or acute -LRB- 4 -RRB- time points	37219
subacute	37226
acute -LRB- 4 -RRB- time points	37238
4	37245
addition	37264
axonal regeneration of brainstem neurons that are involved in different aspects of motor function -LRB- 34 -RRB-	37274
axonal regeneration	37274
brainstem neurons that are involved in different aspects of motor function -LRB- 34 -RRB-	37297
brainstem neurons	37297
different aspects of motor function	37336
different aspects	37336
motor function	37357
34	37373
OB-OEG-transplanted versus nontransplanted rats	37402
OB-OEG-transplanted	37402
nontransplanted rats	37429
no differences related to time posttransplantation	37462
no differences	37462
time posttransplantation	37488
the positive correlation between locomotor performance and extent of axonal regeneration	37523
the positive correlation	37523
locomotor performance and extent of axonal regeneration	37556
locomotor performance and extent	37556
axonal regeneration	37592
those brainstem neurons	37640
the motor recovery -LRB- 35-37 -RRB-	37686
the motor recovery	37686
35-37	37706
our results	37720
the effectiveness of adult OB-OEG and tissue repair	37742
the effectiveness	37742
adult OB-OEG and tissue repair	37763
the stage of the scarring processes	37814
the stage	37814
the scarring processes	37827
injured neurons	37860
their capacity to respond to OB-OEG for at least 4 months	37886
OB-OEG for at least 4 months	37915
OB-OEG	37915
at least 4 months	37926
The beneficial effects of OB-OEG	37945
The beneficial effects	37945
OB-OEG	37971
enhanced axonal regeneration , survival and tissue sparing , remyelination , stimulation of angiogenesis , and neuroprotection -LRB- 38-41 -RRB-	37999
enhanced axonal regeneration , survival and tissue sparing	37999
enhanced axonal regeneration	37999
survival	38029
tissue sparing	38042
remyelination	38058
stimulation of angiogenesis	38073
stimulation	38073
angiogenesis	38088
neuroprotection -LRB- 38-41 -RRB-	38106
neuroprotection	38106
38-41	38123
a recent report	38141
OB-OEG	38171
key molecules involved in the response to wounding , blood vessel development , extracellular matrix formation and remodeling , and cell adhesion -LRB- 42 -RRB-	38186
key molecules	38186
the response to wounding , blood vessel development , extracellular matrix formation and remodeling , and cell adhesion -LRB- 42 -RRB-	38212
the response to wounding , blood vessel development , extracellular matrix formation and remodeling	38212
the response	38212
wounding , blood vessel development , extracellular matrix formation and remodeling	38228
wounding	38228
blood vessel development	38238
extracellular matrix formation	38264
remodeling	38299
cell adhesion -LRB- 42 -RRB-	38315
cell adhesion	38315
42	38330
the present results	38344
OB-OEG transplantation at subacute and chronic SCI stages	38376
OB-OEG transplantation	38376
subacute and chronic SCI stages	38402
subacute	38402
chronic SCI stages	38415
a reparative action via any or all of these mechanisms	38452
a reparative action	38452
any or all of these mechanisms	38476
any or all	38476
these mechanisms	38490
remyelination	38508
the present study	38542
Our study	38570
the first evidence	38589
chronic SCI	38613
OEG transplants	38644
Lu et al -LRB- 19 -RRB- and Lopez - Vales et al -LRB- 20 -RRB-	38661
Lu et al -LRB- 19 -RRB-	38661
Lu	38661
et al -LRB- 19 -RRB-	38664
et al	38664
19	38671
Lopez - Vales et al -LRB- 20 -RRB-	38679
Lopez	38679
Vales et al -LRB- 20 -RRB-	38686
Vales	38686
et al -LRB- 20 -RRB-	38692
et al	38692
20	38699
transplantation at the subacute stage , that is	38713
transplantation	38713
the subacute stage , that is	38732
the subacute stage	38732
30 and 45 days	38767
we	38807
adult OB-OEG -LRB- central -RRB- , whereas in the former study , OEG were obtained from lamina propria -LRB- peripheral -RRB- , and in the latter study	38815
adult OB-OEG -LRB- central -RRB-	38815
adult OB-OEG	38815
central	38829
the former study	38850
OEG	38868
lamina propria -LRB- peripheral -RRB-	38891
lamina propria	38891
peripheral	38907
the latter study	38927
neonatal bulbs	38950
It	38966
mucosal OEG	38992
the same migratory or axonal growth-promoting properties	39019
the same	39019
bulbar OEG	39079
rodents -LRB- 16-18 -RRB-	39093
rodents	39093
16-18	39102
neonatal OEG	39114
the same properties	39142
adult OEG -LRB- 24 , 43 -RRB-	39165
adult OEG	39165
24	39176
43	39180
The observation that implantation of adult OB-OEG can improve recovery after SCI and the lack of a decrease in efficacy when used in a chronic stage	39185
The observation	39185
implantation of adult OB-OEG	39206
implantation	39206
adult OB-OEG	39222
recovery	39247
SCI and the lack of a decrease in efficacy	39262
SCI	39262
the lack of a decrease in efficacy	39270
the lack	39270
a decrease in efficacy	39282
a decrease	39282
efficacy	39296
a chronic stage	39318
this	39340
a more realistic paradigm for autologous cell therapy for chronic SCI	39345
a more realistic paradigm	39345
autologous cell therapy for chronic SCI	39375
autologous cell therapy	39375
chronic SCI	39403
the context of possible future clinical applications	39419
the context	39419
possible future clinical applications	39434
it	39473
OEG	39503
the OBs of adult humans -LRB- 44 -RRB- and nonhuman primates -LRB- 11 -RRB-	39528
the OBs	39528
adult humans -LRB- 44 -RRB- and nonhuman primates -LRB- 11 -RRB-	39539
adult humans	39539
44	39553
nonhuman primates	39561
11	39580
These cells	39585
standard incubators	39623
large numbers	39659
serum-containing medium	39679
A culture of a single primate OB	39704
A culture	39704
a single primate OB	39717
approximately 1.5 to 2	39746
10 ^ 6 OEG	39771
10	39771
6 OEG	39774
the short-term -LRB- 10 days in vitro -RRB-	39783
the short-term	39783
10 days	39799
an additional 20 x 10 ^ 9 cells	39818
additional 20	39821
10 ^ 9 cells	39837
10	39837
9 cells	39840
2.5 months	39870
This large number guarantees not only autologous transplantation	39882
This large number guarantees	39882
This large number	39882
guarantees	39900
autologous transplantation	39920
cells for allotransplantation and storage	39965
cells	39965
allotransplantation and storage	39975
These cells	40008
similar axonal growth-related molecules as rodent cells in vitro -LRB- 11 , 44 -RRB-	40028
similar axonal growth-related molecules	40028
rodent cells in vitro -LRB- 11 , 44 -RRB-	40071
rodent cells	40071
vitro	40087
11	40094
44	40098
a key issue in this regard	40107
a key issue	40107
this regard	40122
the demonstration	40137
primate OB-OEG from healthy donors	40160
primate OB-OEG	40160
healthy donors	40180
age	40207
1.5 to 10 years	40216
adult	40249
locomotor recovery	40266
transplantation	40291
paraplegic rodents -LRB- 45 -RRB-	40312
paraplegic rodents	40312
45	40332
The surgical procedures that are compatible with human practice for unilateral bulbectomy and for autologous transplantation into injured spinal cords	40337
The surgical procedures	40337
human practice for unilateral bulbectomy	40386
human practice	40386
unilateral bulbectomy	40405
autologous transplantation	40435
injured spinal cords	40467
safety in nonhuman primates -LRB- 11 , 27 -RRB-	40525
safety	40525
nonhuman primates -LRB- 11 , 27 -RRB-	40535
nonhuman primates	40535
11	40554
27	40558
these data point to the OB as a reliable source of OEG for cell therapy	40574
these data point	40574
the OB as a reliable source of OEG for cell therapy	40594
the OB	40594
a reliable source of OEG for cell therapy	40604
a reliable source	40604
OEG for cell therapy	40625
OEG	40625
cell therapy	40633
A remaining and important issue	40647
A remaining	40647
important issue	40663
the present study	40692
the feasibility of OB-OEG autologous grafting for spinal cord repair	40714
the feasibility	40714
OB-OEG autologous grafting for spinal cord repair	40733
OB-OEG autologous	40733
spinal cord repair	40764
The most probable clinical scenario	40784
a young adult or adult patient who requires stabilization of the clinical condition after an accident	40826
a young adult	40826
adult patient who requires stabilization of the clinical condition after an accident	40843
adult patient	40843
stabilization of the clinical condition	40870
stabilization	40870
the clinical condition	40887
an accident	40916
it	40936
bulbectomy	40962
some time	40973
injury	40989
bulb removal	41013
cells	41027
at least 10 days	41054
enough OEG	41081
transplantation	41096
the experimental condition that would mimic the clinical situation most closely	41126
the experimental condition	41126
the clinical situation	41170
the implantation in the chronic situation of OEG obtained from adults	41209
the implantation	41209
the chronic situation of OEG obtained from adults	41229
the chronic situation	41229
OEG obtained from adults	41254
OEG	41254
adults	41272
We	41280
adult OB-OEG	41293
functional recovery and repair	41330
paraplegic mammals	41364
they	41388
chronic stages	41413
at least a period of 4 months	41457
at least a period	41457
4 months	41478
postlesion with no decrease in beneficial effects	41487
postlesion	41487
no decrease in beneficial effects	41503
no decrease	41503
beneficial effects	41518
the case of an autologous therapy	41541
the case	41541
an autologous therapy	41553
this window	41576
enough time	41610
OEG from the olfactory bulbs and also for patient stabilization	41644
OEG	41644
the olfactory bulbs	41653
patient stabilization	41686
the surgery	41715
our results	41739
the prospect for a future therapy	41756
the prospect	41756
a future therapy	41773
autologous implanted OB-OEG in patients experiencing a severe chronic SCI	41795
autologous	41795
OB-OEG	41816
patients experiencing a severe chronic SCI	41826
patients	41826
a severe chronic	41848
SCI	41865
